bristolmyers squibb company annual report hope experience inspire patient go breast cancer patient julia maasthe bristolmyers squibb mission company mission extend enhance human life provide highestquality pharmaceutical relate health care product pledgeto patient customer employee partner shareholder neighbor world serveto act belief priceless ingredient product honor integrity maker cover breast cancer patient julia maas morning find lump breast size marble yearold julia maas houston say diagnose invasive ductal carcinoma follow surgery radiation chemotherapy apparently cancer free nearly decade cancer recur august time recommend therapy work say maas desperate oncologist university texas anderson cancer center suggest enter clinical trial bristolmyer squibb investigational compound call ixabepilone maas appear enter trial hope experience inspire patient go saysbristolmyer squibb company annual report stockholder ver past year stay tightly focused achieve nearterm goalsof launch new product advance pipeline investing busi nesswhile build longterm vision bristolmyers squibb good progress goal know require reason clear want health care leader futureto differ ence generation come need build longterm growth strong financial performance company strive day realize mission extend enhance human life achieve future growth leadership transform company important way execute strategy sharpen focus area significant medical need establish leadership innovative product renew company culturehow workto drive superior perform ance strong possible commitment accountability ethical conduct interpret mission broadly possible expand access innovative therapy build additional health care capacity part world disease poverty take toll bristolmyer squibb accomplish great deal area specifically increase sale growth driver include new medicineserbitux reyataz abilifyas key inline therapie plavix avaproavalide advanced latestage pipeline launch new drug europe move latestage compound regulatory approval process boost sale significantly health care business provide critical growth stability company strengthen compliance accounting financial reporting provide free discount medicine million people need help build critical communitybased health care infrastructure company large initiative address hivaids pandemic southern west africa chairmans letter opportunity challenge prospect company total net sale continue operation increase percent overall performance help growth new inline pharmaceutical product strength health care business impact weak dollar earning ahead plan consensus view investment community decline prior year largely ongoing impact loss exclusivity important pharmaceutical product include monopril paraplatinand glucovance exclusivity loss remain challenge near term bristolmyer squibb entire pharmaceutical industry year patent expire industry key product realize peter dolanchairman chief executive officer billion total revenue industry continue face steadily increase cost associate research develop change environmental factor affect com ment time government pany sectorto find well way build leader payor put downward pressure drug ship growth future decide great price urge company concentrate opportunity lay focus pharmaceutical busi find new medicine provide meaningful ness specific disease area significant unmet marginal benefit exist therapy need innovative medicine help people safety important focus illness attention area cancer hivaid affective psy light reality come pretty chiatric disorder diabete atherosclerosisthrombosis straightforward conclusion pharmaceutical compa hepatitis rheumatoid arthritis obesity alzheimer ny include bristolmyer squibb change disease solid organ transplant rejection fundamentally want continue thrive halfway fiveyear engine innovation improvement health shift pharmaceutical portfolio support care successful growthoriented business strategy position vital company industry beand future say sale see asan essential constructive vibrant new exist product largely offset solution rapidly evolve health care decline sale product lose exclusivity need challenge tomorrow earning share continue come pre bristolmyer squibb implement transfor sure remainder transitional period mational strategy design help achieve goal include year year ago revisit pipeline project prod reason generally uct portfolio business modelcarefully evaluate growth driver carry low margin bristolmyer squibb company annual report product lose exclusivity continue execute strategy invest significantly research development let provide detail growth strongly believe invest progress execute strategy past pipeline opportunity right thing year plan long termeven negative impact thank growth new inline earning short term product gain pipeline number expect picture turn important licensing achievement grow begin exposure exclusivity e presenceor potentially meaningful presencein loss greatly reduce year nearly disease area mention early new product begin contribute meaningfully cancer erbitux treatment revenue earning growth advance refractory colorectal cancer scenario assume continued exclusivity codevelope comarkete imclone system plavix antiplatelet medicine incorporate launch lead product sale billion begin erbitux help focus medical need primary patent plavixwhich confer exclu thousand people colorectal cancer hope sivity currently chal benefit cancer patient information lenge generic drug company believe available clinical study patent valid infringe imclone currently way plan initiate generic company andtogether alliance oncology pipeline license late partner sanofiaventiswe defend vigorously stage anticancer medicine vinflunine strategy focus primarily trans javlor pierre fabre mdicament france form pharmaceutical business nonphar metastatic bladder cancer mdx maceutical health care businessesmead johnson medarex inc metastatic melanoma nutritional convatec medical imaginghave advance laterstage oncology compound contribute greatly company financial strength laboratory ixabepilone breast cancer stability help fulfill srcabl kinase inhibitor chronic override mission myelogenous leukemia recently transi collectively business deliver yearover tione phase registrational program year profit growth nearly percent grant fast track designation food account approximately quarter overall drug administration fda earning percent net sale continue area psychiatric disorder abilify generate solid growth thank innovation remain successful new product market expansion continue introduction history pharmaceuti important company future cal industry codevelope comarkete chairman letter abilifywhich initially approve treatment rheumatoid arthritis fda grant priority schizophreniawith otsuka pharmaceutical review status baracludeand fast track designation company ltd year market abatacept baracludealso submit abilify capture great european regulatory authority altogether percent share weekly new prescription promise compound development antipsychotic class total worldwide sale include regulatory approval process bristolmyer squibb otsuka annualizing compound broad rate billion development portfolio gain important additional indi pipeline continue advance distin cation abilify treat acute mania guish especially proud productivity bipolar disorder recently receive approval commitment organization nearly drive superior performance maintenance therapy certain patient third company compound currently bipolar disorder launch product developmentinclude european union key european mar regulatory reviewwere discover ket abilify fast uptake new laboratory inlicense remain important atypical antipsychotic believe component strategy dramatic transforma beginning realize potential impor tion favor capability tant treatment psychiatric disorder step build sustainable growth leadership hiv protease inhibitor reyataz continue future potentially significant grow share follow launch percent exploratory develop july nearly percent ment compound come inhouse effort weekly new prescription protease inhibitor license give strong impetus second prescribed therapy class building leadership disease area focus launch reyatazin seven european mar currently collaboration ket uptake region vigorous approximately company research achieve great percent institution world share france nearly percent share know invest germany engine prime run increase number disease area pipeline overall expenditure percent billion pave way potential future leadership significant portion growth go sup company plan advanced port latestage pipeline opportunitie major regulatory approval process latestage area investment biologic capability compound baracludeentecavir hepatitis require costly complex infrastructure muraglitazar diabete abatacept biologicslargemolecule proteinsare bristolmyer squibb company annual report important laboratory industry acade mia government apply new understanding richard gelb disease process increasingly target treatment erbitux company biologic product investigational biologic richard gelb join bristolmyer pipeline include abatacept rheumatoid total revenue stand arthritis belatacept prevention solid organ million fortyfive transplant rejection mdx cancer year later company say vigorously pur eventually lead ceo year sue pipeline product opportunity chairman board margin come pressure result year total net sale ongoing exclusivity loss reason ask approach billion entire organization reduceor minimum growth dick gelbs endure legacygrowth company size value impact hold flatall spend nonpriority area purpose lead effort acquire mead johnson nutritional successful building right culture business responsible build important way transform company leadership position pharmaceutical product research great engineering bristolmyer squibb build future growth merger bristolmyer company squibb leadership renew strengthen corporationa combination create company culture translate drive superior large pharmaceutical company world performance organization dick gelb ceo prescription drug account quarter company sale end ensure strong possible commitment tenure pharmaceutical medical device accountability compliance ethical conduct account percent sale create important new structure role medicine company portfolio process area human resource finance continue grow contribution limited company compliance extend world large example link performance behavior work bristolmyer squibb foundation closely develop communicate example initiate know organization set critical behavior bristolmyer squibb freedom discoverunrestricte biomedical research grant awards program define conduct employee core bms date effort large kind cor behavior include key attribute leadership porate america commit million communication alignment nostringsattache support expand frontier essential factor attain goal scientific understanding grant insti tution country personal level dick executive senior manager gelb generous anonymous backer evaluate demonstrate behav worthy cause help individual strengthen ior compensation tie community support civic institution assessment complement core behavior dick gelb accom plishe legacyof commitment advance company pledge standard business mission bristolmyers squibb extend impact conduct ethic commit employee grow contribution world largewill perform duty high ethical standard remain everlasting model leader continue strengthen financial control account critical task year chairman letter essential constructive vibrant solution health care challenge ensure effectiveness internal control implementation medicare modernization financial reporting require section act help senior citizen sarbanesoxley legislation pleased well afford medicine recently assess effectiveness outside donate nearly million control conclude engaged medicine product people need operate effectively require legislation provide million direct assis independent register public accounting firm tance million donate medicine issue report assessment appear product tsunami relief effort south asia annual report especially proud people bristolmyer finally additional significant resource squibb donate compliance activity past year fund tsunami relief contribution enlarge corporate compliance councilwhere match dollar dollar bristolmyer issue policy thoroughly review squibb foundation name compliance leader finally help build strong healthy business continue train personnel community part world devastate compliance awareness improve resource hivaids pandemic announce establish helpline employee anonymously ment additional medical center treat chil ask question report concern dren family hivaids southern africa fund million secure healthy future futureinitiative centerswhich sche believe leader building ule open late model success healthy future company world ful bristolmyer squibbfunde pediatric clinic large define mission extend botswana open today enhance human life broad possible term large aid center child world course mission include vitally important date secure futureha commit role discover develop provide innova funding project country southern tive medicine disease quality west africa impact hivaids health care product help improve life severe january opportunity visit commitment begins end secure futureproject botswana help expand access pharmaceutical swaziland south africa heartened take lead role variety initiative firsthand difference initiative make discount card senior life woman child citizen recently access community individual live card uninsured people year age work contribution patient assistance support secure futureof wide range program provide approximately million innovative communitybase initiative aim free medicine million people help develop sustainable health care capacity look forward greatly need fight aids bristolmyer squibb company annual report look look ahead think dick james proud closing want thank board director company stay true value invaluable support counsel past ideal build accomplishment year dedicate bristolmyer success squibb employee world treman look ahead plenty opportunity dous accomplishment commitment goal expand achievement past build healthy future success pleased welcome new board year continue execute strategy member james cornelius nonexecu build leadership growth address area tive chairman guidant corporation significant unmet medical need work want acknowledge outstanding hard foster company culture put contribution extraordinary colleague great emphasis strong performance drive sadly pass away strong value dedicate effort richard gelb chairman emeritus expand access innovative medicine giant business leader regard build health care infrastructure resource chairman chief executive officer year develop world tall order span dick build bristolmyers squibb power ambitious know house scientific innovation financial strength successfuland leader tower figure beat heart companieslike peoplehave great hope truly compassionate committed man future report hope day live mission value pledge good health universal bristolmyers squibb author job turn hope reality people value mentor dear friend measure success james palmer chief live mission today scientific officer president pharmaceutical future research institute brilliant scientist devoted life turn scientific knowledge lifesave therapy bring james com pany respect greatly recent pipeline achievement represent fruit vision peter dolan chairman chief executive officer leadership company reflect remark march able ability inspire excellence colleague pri unexpected death diminish pharmaceutical pipeline pharmaceutical pipeline bristolmyer squibbresearcher dedicate report attention impor discover develop innovative medicine tance ongoing clinical trial highlight response address significant medical need key disease area individual clinical trial patient area list chart select individual story case study hope result emphasis future medicine patient unpredictable individual experimental study par need match internal strength ticipant personal account illustrate importance growth driversare approve medicine participation clinical trial essential drive current future growth continue development generation medical innovation clinical development determine additional indi true test turn hope reality cation benefit patient registrationalcompound patient document real clinical bene advance investigational drug submit fit significant number research participant regulatory agency approval ability bring new product patient need find process submit developmentcompound new use current product dependent latestage clinical development hope demonstrate safety effectiveness favorable bene submit approval year compound fitrisk relationship systematic testing patient exploratory developmentare preclinical early volunteer participate study like clinical development compound research program scientific endeavor clinical testing novel drug compound discoveryare early stage development complex timeconsuming resourceintensive process investigational compound research program rep guarantee result describe bristolmyer resent chart dot compound squibb commit pursue endeavor vigorously discuss special report hope begin bring new hope patient disease growth registrational exploratory discovery area driver development development affective psychiatric disorder alzheimer disease atherosclerosis thrombosis cancer diabetes hepatitis hivaids obesity rheumatoid arthritis solid organ transplant rejection inlicense discover bristolmyer squibb abatacept process submit approval hope special report hopeis powerful idea faith belief future hope inspire people act transform dream reality peoplesuch julia maas cover edie hudgin picture patient feature page followhope find investigational clinical trial otherslike scientist bristolmyer squibb employee hope promise deliver innovative product patient need special report learn develop new medi cine health care prod uct expand access therapy create sustainable health care program neediest bristolmyer squibb live mission extend enhance human lifeand beacon hope shine brightly kidney transplant patient edie hudgin edie hudgin conyer georgia apparent good health sudden autoimmune condition attack kidney send emergency room leave dialysis yearold daughter donate kidney shortly transplant operation hudgin enrol clinical trial investigational immunosuppressive compound call belatacept prevent transplant rejection feel help road worth saysspecial report building hope medicine create growth driver approvalsuccessful launch erbitux key erbitux cetuximab work growth new medicine represent fight cancer lie ability selectively target epider culmination year intense lab mal growth factor receptor find surface oratory clinical study human cancer include colon rectum new medicine begin today novel monoclonal antibody success continue journey discovery fully appropriate patient metastatic colorectal cancer erbitux abilify plavix reyatazand hope key open door treat avaproavalide successfully solid tumor bristolmyers squibb partner launch productalready significant imclone system incorporate implement compre grow company hensive clinical development plan investigate utility portfolio hopefully erbitux nonsmall cell lung pancreatic begin tap potential benefit cer submission plan head patient neck cancer new therapy head neck cancer bristolmyer squibb devel approve fda ope medicine day pleased bristolmyer squibb imclone opportunity morefor invest program develop erbitux area patient unmet need say martin birkhofer vice president family employee growth driver profile erbitux global development champion bristolmyer section special report squibb reward come offer hope future colon cancer patient work able difference live patient cancer bipolar disorder patient chuck conein chuck coneinof deer park washington realize simply stress brain feel like set change channel time conein say end hospital diagnose bipolar disorder year prescribe medication point medicate drive recently doctor suggest abilify finally say conein feel control life abilify mark altmeyer senior vice president treatment acute bipolar mania recently neuroscience marketing bristolmyer approve maintain efficacy certain squibb know medicine patient bipolar disorder abilify like abilify aripiprazole help difference unique pharmacology profile bristolmyer live individual keep letter squibb partner otsuka pharmaceutical desk remind day ltd explore additional use woman psychiatrist thanking study suggest abilify work differently prescribe abilify say year different condition raise level certain sure life worth live neurotransmitter low reduce lev try lot medication el high special type activ work doctor prescribe abilify ity mean abilify potentially play important letter say come shell role disease currently investigation abilify benefit hundred altmeyer understand possibility thousand patient suffer challenge worth say psychotic disorderschizophrenia hold letter hand abilify approve fda come work day heart attack patient otello brighi hadany health problem morning say otello brighi ravenna italy day feel sudden pain chest arm diagnose myocardial infarction brighi recover november doctor recommend enter investigational clinical trial determine plavix help prevent second heart attack heart attack distant memory say brighi future look hopebuilding hope special report reyataz reyatazatazanavir sulfate launch bristolmyers squibb june eighth drug class plavix trust plavix member protease inhibitor pis family say brian gavin phd global approve oncedaily dose medical affair director plavix clopidogrel year reyatazbecame secondmost bisulfate doctor prescribe plavix prescribe reyatazi uncle greataunt cardiovas internationally combination therapy cular peripheral vascular disease plavix treatment hiv help protect aunt uncle future vascular event heart attack stroke amazed mother suffer series people tell stroke candidate plavix grateful benefit plavix confer todayin reduce risk heart attack stroke appropriate patient follow myocar fourpart clinical development pro dial infarction stroke acute coronary gram seek expand utility reyataz syndrome peripheral arterial diseasethere patient hope program learn provide additional information use landmark clinical study reyatazfor new patient evaluate serve foundation understand current lipid resistance profile provide new use plavix patient major formulation complete investigational study ongoing seek evaluate effec study pediatric patient tiveness plavix patient risk wide oncedaily dose minimal lipid effect spectrum lifethreatene thrombotic event establish efficacy safety profile altogether bristolmyer squibb partner important consideration patient live sanofiaventis mount large hiv say ron cooper senior vice presi clinical trial program developedtotale dent virology aids service organi patient worldwide zation patient group physician office truly challenge reward amazed people approach experience work plavix say gavin tell grateful bristolmyer family likely agree squibb hearing speak passionately positive impact include reyataz hiv combination therapy life make feel absolutely proud special reportbuilding hope registrational soon anticipate growth muraglitazar tell cindy rubin group driversthose medicine outline director metabolic disease global clinical research page complement diabete health problem know firsthand investigational compound devastating diabete say developed address additional internist treat patient type diabete medical condition type patient diabete medical diabetes mellitus hepatitis virus condition dyslipidemia cardiovascular disease infection rheumatoid arthritis kidney eye major depressive disorder know firsthand damage registrational com challenge devastating pound submit regula blood tory approval process diabetes glucose good submit threemuraglitazar abata control manage cept baracludewere discover associate condition complication bristolmyer squibb scientist diabetes grow worldwide health crisis fourth emsam selegiline transdermal million people suffer diabete include system enter bristolmyer squibb million americans remain undiagnosed pipeline december follow commercialization agreement unfortunately current treatment fail achieve somerset pharmaceuticals inc good control disease patient diabetes somerset receive approvable approve muraglitazar letter fda february new class investigational compound call glitazar approve emsam dual alphagamma ppar peroxisome proliferatoractivate transdermal treatment major receptor activator design improve glucose depressive disorder muraglitazar lipid abnormality associate type diabete abatacept baracludeare profile base clinical finding date section patient say rubin believe muraglitazar potential help diabetic patient well control blood sugar level april bristolmyers squibb enter global collaborative agreement merck inc jointly develop market muraglitazar new drug application nda marketing approval muraglitazar submit fda december rheumatoid arthritis patient mike hayward rheumatoid arthritisturne simple activitieslike unscrew jar lift package walk stepsinto impossible feat yearold mike hayward philadelphia ache say ladder carpentry job stop shoot pool friend enrol investigational clinical trial abatacept say hope achieve normalcy abatacept rheumatoid arthritis treat symptom say michael body literally erode away joints chronic corbo phd vice president abatacept progressive autoimmune abatacept design global development disorder affect abatacept design million people world actually target wide treat symptom critical step diagnose autoimmune process stop work disability suffer decrease clinical trial patient quality life reduce life span support abatacept development biologic advance treatment license application process rheumatoid arthritis significant issue remain submit fda marketing approval majority patient suffer disease fda grant abatacept fast track status abatacept investigational compound designation facilitates review drug potential new class agent call selective potentially address unmet medical need costimulation modulator design disease hepatitis patient donghui zhao donghui zhao live beijing wife teenage son mother die liver cirrhosis test positive hepatitis virus hbv probably acquire birth say begin feel extremely tired look ing place rest sleep despite treatment serum hbv level rise significantly enter investigational clinical trial baraclude enter trial feel like healthy person say zhao believe science baraclude million people year work worldwide infect hepatitis virus team begin pay hbv chronic hbv infection cause liver patient japan cirrhosis liver cancer million people china enrol baracludeclinical trial die annually baraclude exciting program september complication bristolmyer antiviral compound hbv ninth squibb submit lead cause death worldwide nda fda baracludeas market baraclude entecavir investigational nucleo ing authorization application european analog block stage hbv medicine agency fda grant baraclude replication process baracludeis exciting antivi priority review classification apply time ral compound say richard colonno phd vice submission drug approve president infectious disease drug discovery significant improvement treatment recently opportunity jog disease compare market product baracludeclinical trial patient say colonno cross finish line baraclude meaningful experience say colonno hope help people scientist meet baracludetreate patient world address disease building hope special report development bristolmyer squibb today belatacept work richard wright phd compound development motivate desire help patient day include advanced clinical think improve life patient say development development think mother friend underwent closely follow heart transplant year ago risk registrational compound develop kidney dysfunction effect pipeline moreadvance investi immunosuppressant therapy look forward gational compound ready able offer transplant patient potentially submit regulatory agency toxic alternative marketing approval europe patient year investigational live transplant organ receive ultimately submit ted approve day think compound represent possibility improve life address significant medical need patient development present section belatacept new transplant year prevent rejection transplant prevention solid organ transplant recipient require lifelong therapy potent immuno rejection srcabl kinase inhibitor mdx ixabepilone suppressive drug unfortunately longterm therapy treatment cancer additional contribute high blood pressure high cholesterol development compound edifoligide level diabete kidney toxicity transplant prevention vein graft failure patient risk death cardiovascular disease prema javlor vinflunine cancer ture graft loss bristolmyer squibb scientist engineer belatacept compound discov ere developed block specific pathway tcell activation believe good mind biomedical science initiate transplant rejection explore heart scien investigational approach reduce occurrence tist drive transplant rejection cause few effect tradi good story tional immunosuppressant say wright vice president global brand champion belatacept phase clinical trial involve kidney transplant patient treatment belatacept produce promising result excite result say wright confirmed phase iii trial believe belatacept potential exciting new option kidney transplant patient chronic myelogenous leukemia patient cheryl iantorno march cheryl iantorno life come halt diagnose chronic myelogenous leukemia want believe fatal disease say iantorno irvine california august treatment fail october say bone ache incoher ent barely bed enter clinical trial bristolmyer squibb investigational srcabl kinase inhibitor stand research drug work say iantorno hope srcabl kinase inhibitor chronic patient resistant agent myelogenous leukemia cml fatal compound potential anticancer cancer bone marrow fortunately treat activity solid tumor type include ment evolve fervent prostate colorectal small recent year cell lung gastrointestinal wish availability imatinib cancer preclinical study know help patient multiple tumor type gleevec early clinical trial resistant exist agent result patient cml promise therapeutic option available nicaise hope accelerate development bristolmyer squibb scientist discov program confirm result january ere potential firstinclass compound fda grant srcabl kinase study determine ability inhibit inhibitor fast track status src abl pathway cell mechanism happen know yearold cml involve growth progression patient undergone bonemarrow tumor type include cml say claude transplant need frequent platelet transfu nicaise vice president srcabl global sion say nicaise enter clinical trial development srcabl kinase inhibitor srcabl kinase inhibitor july potent vitro hope work fervent wish help patient build hope special report mdx melanoma cancer pigment produce cell skin remain difficult form cancer treat year ixabepilone david chuan lee case diagnose world lead development team ixabepilone wide people die new investigational cancer drug cancer disease november bristolmyers squibb remain develop medarex inc new jersey biopharmaceuti effective treatment common cal company announce worldwide collabora cancer say lee know father tion develop commercialize potential diagnose lung cancer pass new treatment melanoma call mdx away christmas mdx fully humanize antibody discover bristolmyer squibb target ctla molecule surface scientist ixabepilone new tcell responsible shut drive immune response explore mdx help patient immune new hope ixabepilone system effectively fight tumor bring bristolmyer squibb medarex conduct pivotal phase iii melanoma study class anticancer drug know epothilone phase study ongoing cancer design avoid mechanism type include renal cell prostate breast think important drug resistance lee encourage see say offer hope patient early clinical study say rachel humphrey respond stop respond vice president development treatments mdx look forward result phase clinical trial thou phase iii trial signify unmet sand patient receive ixabepilone medical need promise novel therapy variety tumor type include breast compound receive fast track review lung prostate pancreatic renal cancer status fda additional patient enrol think mdx phase iii trial metastatic breast cancer think patient treat year half member ixabepilone team ago say humphrey drive possibility develop com small lump second week pound work treatment terrible pain fourth week stop work say lee son dead unfortunately fail lose dad cancer drive new respond available treatment wish hope ixabepilone bring patient give option cancer family chance mdx represent option potential ray hope someday able provide patient special reportbuilding hope discovery bristolmyers squibb goal deliver discovery step long process drug steady stream innovative new med discovery find good therapeutic target prove icine patient need worldwide relevance fighting disease match target feeding stream source novel compound step year company drug discovery engine new medicine arise mind scien lie foundation pipeline sus tist envision novel therapeutic approach tainability say francis cuss begin silicon synapsis advanced drugdesigning frcp senior vice president drug computer synthesize automate high discovery focus throughput chemical assembly line elementsimprove productivity multidisciplinary team talente scientistsworking discovery process deliver leadingedge technologiesfirst design refine highquality drug candidate clinical compound discover promise compound test consistent basis enhance subsequent development evaluate modify process call drug optimiza success rate tion work closely biologist chemist minimize molecule undesired effect maximize section special report desire effect say richard robertson phd senior offer brief overview com vice president drug safety pharmaceutical candidate pany approach discovery optimization result compound high element fuel product pipeline create hope potency low potential toxicity future cuss team scrutinize aspect drug discovery process eliminate redundancy improve quality quantity drug candidate half early drug candidate come company lab enter human testinga success rate average industry proportion early candidate enter clinic increase percent industry success rate rise percent good example company approach oncology discovery program recently introduction new tech nologie combine advance genomics biochem istry generate explosive growth cancer research productivity result new generation highly target selective anticancer compound development today new compound emerge bristol myers squibbs discovery labs technical name describe specific cellular target novel mechanism action hiv researcher pinfang lin phd john kadow phd good compoundrequire dedicate team discover develop biologist pinfang lin director hiv drug discovery john kadow direc tor virology chemistry working bristolmyer squibb investigational hiv attachment inhibitor program multiple compound early clinical development compound design block hiv attach receptor say kadow potentially help prevent virus gain foothold lin biologist profile compound potency toxicity safety pharmacology viral resistance want help people suffer hivaid say lin find new hope enter range selective computer model sophisti orally active kinase golden era cat image genomic robotic inhibitor target drug discovery rely spec vegffgf receptor inhibitor trum hightech tool technology experimental anticda agonist monoclonal story say john houston phd antibody design stimulate cancer vice president apply biotechnology patient immune system stop reverse tumor discovery biology final product growth early development nextgen depend human intuitionthe scientific eration androgen receptor antagonist design insight innovation drive biologist target drugresistant prostate cancer chemist carl decicco phd vice president enter golden era discovery chemistry agree enthusiasm position harvest fruit scientific excellence set apart decade cancer research say cuss ability tackle challenge human disease oncology disease area scientist unrelente focus medical apply approach result need effort improve success rate proliferation compound discovery deliver early pipeline believe exploratory development oncology good company history say cuss company disease area bristolmyers squibb discovery poised pharmaceutical pipeline deliver future patient special reportbuilding hope health care business bristolmyer squibb employee mead johnson nutritional research world dedicated give food think discover develop innovative evident mead johnson nutritional product provide real value history say stephen golsby mead johnson presi offer significant benefit people dent mead johnson leader infant child need commitment nutrition responsibility commitment embed mission value seriously infant child great start life run entire company lipilline nutritional product case point pharmaceutical business mead johnson introduce enfamil lipil related health care infant formula include dha nutrient find product business breast milk important brain eye development section glimpse scientist mead johnson take idea businessesmead step fartheror step depend johnson nutritional infant child point view know baby prior birthand nutrition product bristolmyer squibb breastfe baby birthdepend mother medical imaging cardiovascular imaging dha intake dharich food rel product convatec ostomy atively low compare area world wind therapeutic sense passion moti infant receive adequate dha vate employee drive pregnancy address concern mead johnson difference people life launch expectalipil supplement provide dha pregnant nursing mom study demonstrate well visual acuity well mental development infant feed enfamillipilwith iron versus formula lipil say deborah diersen schade phd mead johnson global regulatory scientific affair addition breastfe infant mother take dha supplement like expectalipilshowe improve cognitive performance year age mead johnson researcher understand nutrient significant impact infant critical year life breast feed infant formula say diersenschade know important time term growth development help baby reach great potential mother newborn tammy hawk tammy hawk chicagois mom appreciate addition dha nutrient mead johnsons lipil line product important brain eye develop ment hawk pregnant connor month old husband want good head start life hawk work public relation firm serve mead johnson hear expectalipildha supplement soon launch take expectalipilto provide dha utero birth feeding connor enfamillipil iron infant formula think woman look way good care baby say hawk pregnancy afterwardsspecial reportbuilding hope medical imaging innovator heart employee bristolmyer squibb convatec aquacel introduce medical imaging word com convatec antimicrobial pany mission commit search wound dressing incorporate innovative new way deep human gelling property hydrofibertechnology heart vasculature absorb time weight innovation define bring mis wound fluid eliminate need daily sion life behalf customer painful dress change patient say cory zwerling medical imaging simple concept create technology take year hard work begin proud say phil bowler mphil director forefront microbiology antiinfective convatec deeside england realize cardiovascular imaging true technical differentiation hydrofiberfrom fibrous dressing know benefit president focus leader unique property likely bring patient field cardiovascular imaging benefit hydrofibertechnology key continued success increasingly realize physician decade cardiolitekit worldwide say gary restani presi preparation technetium tcm sestamibi dent convatec researcher injectionthe successful radiopharma take technology new level ceutical everha provide physicians vital nextgeneration hydrofibertechnologyin information blood flow heart muscle year new chemistry enable recently definityvial perflutren lipid convatec design develop gelling wound microsphere injectable suspension dressing product increase versatility help physician bring clarity unevaluable nextgeneration technology echocardiogram patient doctor able finetune dressing medical imaging work shape fit patient nature wind future cardiovascular imaging pipeline say michael lydon phd vice president product help create new standard convatec wound therapeutic care current program include explore technolo physical polymer chemist dave parson gy assess vulnerable plaquethe lead phd explain potential benefit cause heart attackdevelope highly selec wound dressing technology enable tive pharmacologic stress agent potential dressing look like traditional gauze dressing improve patient tolerability advantage modern hydrofiber promising innovation product say help medical profes mission drive sional transition traditional treatment business zwerling say proud modern wound care forefront cardiovascular imaging burn patient mark wilson industrial electricianmark wilson oklahoma city work electrical equipment flash fire engulf flame suddenly stand cloud smoke flesh hang shin recall wilson sustain severe burn arm leg face local burn center treat aquacel agantimicrobial wound dress hydrofibertechnology wilson probably need skin graft extend hospi tal stay instead treat outpa tient basis return work month feel blessed need multiple skin graft say glad able home quicklyspecial report foster hope expand access health care hope precious commodity access bristolmyers squibb join work pharmaceutical company comprehensive ner bristolmyers squibb seek lift prescription saving program offer pharmaceuti barrier treatment people cal industry rxcard help participate circumstance prevent senior qualified medicare recipient save purchase medicine brandname prescription medicine discount prescription pharmacy congress pass programslike senior medicare prescription drug improvement modernization drug benefit act plan assist cardholder end access new drug benefit available uninsured offer qualify rxmember company make individual help hand real difference people need say tom mckenna thousand indigent patient vice president business process far company patient assistance enrol million medicareeligible beneficiary foundation oncologyvirology collectively save millionan average access program provide medicine prescription people cost partnership sign prescription assistance provide single resource allow patient accessa saving program qualify navigate way well health uninsured people eligible outside program offer medicare introduce january significant discount help access card get individual meaningful accessible hiv medication saving brandname prescription medi cine product include bristolmyer section outline approach make hope squibb say mckenna accessible great need bristolmyer squibb patient assistance foundation incqualifie patient live prescription drug insurance company physician methodist minister scott morris mdiv scott morris realizeda childhood dream found church health center memphis tennessee patient uninsured sick stick say morris place turn morris encourage patient apply aid bristolmyer squibb patient assistance foundation able dispense medicine free charge disadvantaged people program tremendous help say morris imagine caring decision company help people genuinely need prescription medication charge bristolmyer squibbamericare program easy patient physician oncologyvirology access program help useone million plenty reason reach indigent patient fill government program grow year prescriptionsat begin chargefor company plenty pharmaceutical value cover everybody government pro million gram wholesale price cover everybody say james prazak bristolmyer squibb participate rph vice president bristolmyers squibb partnership prescription assistance ppa patient assistance foundation program industry program help lowincome help people access medication say uninsured patient free nearly prazak lead productive life free brandname medicine ppa chance improve situation available state expect patient assistance foundation available nationwide april idea special reportfostering hope contact information access program united states wwwtogetherrxcom access wwwtogetherrxaccesscom bristolmyers squibb patient assistance foundation bristolmyer squibbamericare oncology virology oncologyvirology access program virology partnership prescription assistance wwwpparxorg convatec ostomy assistance program mead johnson help hand program child physician coordinate local specialty infant formula mead johnson representative central website tollfree num government increase access sustainable ber people financial difficulty prevention care treatment hivaid find assistance available bristolmyer squibb assist develop say country discount percent randy alsman senior price job vice president hiv drugs videx give people need strategic access didanosine zerit domestic stavudine say john reasons hang patient assistance mcgoldrick bristol hope initiative eligible myers squibb executive patient need include vice president general free convatec ostomy product discount counsel far develop free product mead johnson nutritional country participate subsaharan infant require specialty formula african country commit price outside united profit company nationsindustry accelerate access initiative goal initiative bristolmyer squibb reach help help fulfill mission extend enhance people develop country stricken human life say alsman end hivaid begin company day program job work pharmaceutical com give people need reason hang panie united nations agency hope special report create hope well health sustainable program child bristolmyer squibb seeks create hope consider hivaids africa sustainable solutionsto responsi steady drumbeat negative news devastation ble neighbor citizenacross hivaid bring african continent say front people need mark kline director baylor international effort company pay pediatric aid initiative turn corner special attention child baylor partner bristolmyers squibb child represent future create groundbreake hivaids treatment program hope eternal child child think time hope optimism vulnerable child family affect hivaids kline year million child add infrastructure human capacity build develop country die care treat hivinfecte child family fifth birthday southern africa partnership company secure percent death child futureprogram local government klines group year old cause open clinical center botswana hivaids latin america africa devote exclusively treat hivinfecte caribbean year child family train health care professional child year old succumb pediatric aid conduct clinical research preventable treatable illness child underrepresente long obesity childrenespecially minoritiesha reach epidemic kline say center month operation proportion grow percentage botswana test child youth diabete type child treatment likely large disease exclusively diag concentration hivinfecte child treat nosed adult overweight world thrill bristolmyer critical risk factor development squibb agree highly successful model hopeeven fund additional center swaziland lesotho appear lose special reportcreating hope latin america bristolmyers squibb address issue obesity child create new measure hope able inner city highrisk community speak grant catholic obesity crisis africanamerican medical mission board cmmb working community say canada hope partnership pan american health come set good practice chil organization seek implement strategy dren eat healthy food exercise reduce childhood mortality improve regularly influence parent family community practice home man think meal agement common illness clinical bristolmyer squibb backyard skill health worker project utilize mercer county new jersey innovative network faith nership robert health base organization wood johnson reach hope university hospital million people hamilton building hope central american groundbreake caribbean country obesity type say rabia mathai phd cmmb senior diabete screen program support vice president program bristolmyers bristolmyers squibb foundation com squibb foundation trailblazer interna pany local contribution program say hospital tional health pharmaceutical president ceo christy stephenson company come forward join hand past year certify diabete educa partnershipto leverage faithbased network tor work school nurse screen provide health care world child local school noninvasive ministry health mean measure identify kid high risk type provide total health care percent diabete refer program health care vulnerable population provide prevent onset disease faithbase organization like second phase partnership area fabric community bristolmyer squibb bristolmyers squibb form critical mass platform foundation funding program enable create people come parent child join shapedown early intervention education special week course focuses provide today offer hope tomor healthy eating lifestyle behavioral row helping avoid future health epidemic change issue selfesteem new york central harlem geoffrey treat child stephenson say canada president harlem childrens zone family affair generosity communitybase organization begin foresight bristolmyer squibb working child family able family program threeyear bristolmyer squibb programsand foundation grant create model program mexico vietnam thailand secure future bristolmyer squibb groundbreake secure futureinitiative take forceful stand rise tide hivaid pandemic especially child pandemic vulnerable victim southern africa percent death child cause hivaidsshapedown program past year jason marcus west windsor new jersey enjoyed benefit participate unique familycentere weight management program call shapedown include fitness component nutrition education offer locally robert wood johnson university hospital hamilton rwjuhh say mother jill program raise jason awareness healthy eat need stay healthy help child stay fit healthy life involve entire family thank grant bristolmyers squibb foundation rwjuhh shape program widely available eastern europeall support adopt bristolmyer squibb foundation work wide range sustainability goal focus ner focus child child outside company child addition world bristolmyer employee base new jersey connecticut squibb employee benefit innovative onsite children child hope healthier safe environ development center ment instance puerto rico employee proverb stephenson add work area schoolchildren environmental say health hope education include energy water conserva hope bristolmyers squibb tion nazaire france local fueling hope sustainable schoolchildren learningthrough company program focus make right deci sponsor programabout river otter local sion today health child endanger specie facility employee child generation come financial review management discussion analysis consolidated financial statement note consolidated financial statement report management report independent register public accounting firm control procedure fiveyear financial summary management discussion analysis financial condition result operation executive summary ment period end december prior period march company discussion matter restatement previously issue bristolmyer squibb company bms company bristolmyer financial statement sec consent order squibb worldwide pharmaceutical relate health care product com help ensure circumstance lead need financial restate pany mission extend enhance human life company ment recur company take step enhance effectiveness engage discovery development licensing manufacturing marketing disclosure control procedure include internal control finan distribution sale pharmaceutical health care relate product cial reporting complete restatement company continue company employ approximately people identify implement action improve effectiveness disclosure company report annual global sale continue opera control procedure internal control financial reporting tion billion sale increase prior year level action contribute significantly company identify additional error favorable impact foreign exchange rate fluctuation sale remained relate prior period reflect restatement accordingly constant billion increase sale key brand new product company restate consolidated financial statement correct offset exclusivity loss old brand international sale error year company continue strengthen increase billion include favorable foreign exchange disclosure control procedure surround internal control financial impact product line achieve sale billion report specifically respect section sarbanesoxley act plavix pravacholplavix sale grow include favorable foreign action include establishment policy procedure exchange impact billion pravacholsale decrease includ enhance compliance focus risk management e favorable foreign exchange impact billion additional product line achieve million annual sale include business environment product lines million annual sale pharmaceutical industry company conduct business annual sale excess million highly competitive subject numerous government regulation sale fourth quarter company sign definitive agreement company product affect significantly competitive fac sell oncology therapeutic network otn business distributor phar tor include product efficacy safety price costeffectiveness marketing maceutical product officebase oncologist january effectiveness product label quality control quality assurance man company announce intends div canadian consumer ufacture operating research development new product suc medicine business cessfully compete business health care industry company support mission extend enhance human life develop demonstrate product offer medical benefit cost highestquality product company invest billion research advantage currently new product introduce company development growth expect increase spendingon compete product therapeutic category drug development accelerate development latestage pipeline market company manufacture brand product subject research development dedicated pharmaceutical product include mile high price generic product generic competition stone payment inlicense development program billion company big challenge globally percentage pharmaceutical sale compare pharmaceutical industry majority innovative product com august company announce enter settlement mercial value usually realize period product united states securities exchange commission sec concluding market exclusivity product lose exclusivity long protect secs investigation wholesaler inventory accounting matter patent subject new compete product form generic settlement reach consent order brand exclusivity loss product company lose major company currently operate sec investigation arise portion product sale short period time company announcement april company experience sub internationally health care industry subject stantial buildup wholesaler inventory pharmaceutical business governmentimposed regulation authorize price price con year primarily buildup prima trol impact company sale congress rily sale incentive offer company company state legislature consider number proposal subsequent restatement restatement consolidate financial state enact law effect major change health care system bristolmyer squibb company annual reportnationally state level drive budget concern medicaid investmentsbehind new product launch redeploy marketing access reimbursement restriction implement state promotional spend old product new product propose example december medicare company submit new drug application ndas prescription drug improvement modernization act mma enact food drug administration fda regulatory approval including provide outpatient prescription drug coverage senior citizen unite baracludeentecavir hepatitis muraglitazar type diabetes state company predict potential impact legislation roll biologic license application bla abatacept potential treat business negative impact ment rheumatoid arthritis expect complete early company pharmaceutical business great federal involvement successful launch investigational compound enhance budget constraint increase likelihood pricing pressure control company strategy transition product portfolio cover future market outside united states company operate disease area discuss environment governmentmandate costcontainment program internal growth vital company future success company european country united kingdom germany provide continually evaluate pursue external possibility alliance market price new medicine pricing freedom limited united collaborative agreement company notable record execute kingdom operation profit control plan germany opera successful licensing arrangement supplement pipeline tion reference price system company face significant delay mar arrangement lead fruitful codevelopment copromotion ket access new product year elapse new comarketing agreement company expect continue complement medicine available national market pipeline additional license product component growth manage care organization mcos play company strategy include entry biologic business require large role competition surround health care industry mco increase investment manufacture facility thirdparty manufacturing seek reduce health care expenditure participant make volume arrangement meet future commercial demand expect generate purchase enter longterm contract negotiate discount new product launch addition company continue maintain pharmaceutical provider market potential create collaboration major biotechnology research institution enhance large pool participant marketing prescription drug mcos life cycle company product portfolio initial approvalcom important company strategy company compete mercialization offer combination therapy product extension inclusion mco formulary company generally success major aspect company strategy relate busi ful major product include ness specifically market sale approach specialist play pharmaceutical production process complex highly regulated great role decision relate patient treatment care particularly vary widely product product shift add manufacturing capacity critical disease area company focus effort lengthy process require significant capital expenditure regula reason company recast business model focus specialist tory approval biologic manufacturing involve complex process primary care physician involve treat traditional pharmaceutical operation company patient select disease area order achieve strategic objec capacity manufacture biologic clinical trial commercial tive company plan moderate sell general administrative launch current capacity manufacture large commercial volume spend year customer model note product limit elimination organizational inefficiency company maintain competitive position market strive uphold position dependent success discover result operation develop innovative product serve unmet medical need follow discussion company result continue operation exclude result relate otn business segregate strategy continue operation reflect discontinued operation company implement new strategy discover develop period present discontinued operation innovative medicine address significant unmet medical need change critical disease area area affective psychiatric disorder alzheimersdementia atherosclerosisthrombosis diabete hepatitis dollar millions hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant company continuously strive create well net sale treatment patient build high quality drug discovery develop earning ment pipeline continue operation company undergone transition pharmaceutical minority interest product portfolio old product line include glucophage franchise income taxis monopriltaxoland paraplatin experience exclusivity loss net sale successful launch new product include abilify treatment provision psychiatric disorder reyatazfor human immunodeficiency virus hiv income taxis erbitux cancer portfolio refocus growth brand effective tax rate fall critical disease area target specialist highvalue earning primary care physician sale product disease area continue operation increase steadily expect comprise half pharma net sale ceutical product sale end company make significant change excess bristolmyer squibb company annual reportnet sale invoice wholesaler record defer revenue gross invoice sale price net sale continue operation increase billion classifie inventory hold wholesaler consignment inventory favorable impact foreign exchange rate fluctuation net company cost inventory company recognize revenue sale remain constant billion compare net gross net sale adjustment discuss involve growth prescription demand key brand include plavix avaproavalide significant estimate judgment risk reward ownership sustiva new product introduction include abilify reyatazand transfer customer later inventory erbitux offset low sale product result exclusivity loss sell wholesaler customer firstin firstout fifo basis formonopril paraplatinand glucophage franchise net sale increase company aggregate cost pharmaceutical product billion international net sale increase account consignment model accordingly reflect billion billion exclude favorable consignment inventory company consolidate balance sheet foreign exchange international net sale increase billion significant december defer revenue relate exclude favorable foreign exchange growth sale pri inventory pharmaceutical product account consign marily attributable increase sale plavix avaproavalide launch ment model fully work december defer revenue reyatazand abilify europe offset decline pravachol net record gross invoice sale price approximately million sale continue operation increase billion include december approximately million million million favorable impact foreign exchange rate fluctuation defer revenue recognize respectively composition net increase sale follow correspond effect earning continue operation minority interest income taxis increase million million million respectively volume company recognize revenue gross sale basis deduct vari sell price net ous sale adjustment arrive net sale report consolidated foreign exchange statement earning adjustment refer grosstonet sale increase sale adjustment describe critical accounting policy follow table summarize company grosstonet sale adjustment general company business seasonal information significant category pharmaceutical prescriber demand reference table business segment pharmaceutical section set dollar million forth comparison change net sale estimate total prescription growth retail mail order customer certain company gross sale primary care pharmaceutical product grosstonet sale adjustment company operate reportable segmentspharmaceutical prime vendor chargeback nutritionals healthcare company sign definitive woman infant child wic rebate agreement sell otn previously present separate segment manage health care rebate result operation otn present company contract discount result discontinue operation accordance statement financial medicaid rebate accounting standard sfas accounting impairment cash discount disposal longlive assetsaccordingly otn result operation prior sale return period reclassify discontinued operation conform cur adjustment rent year presentation percent company sale segment total grosstonet sale adjustment follow net sale change increase prime vendor chargeback medicaid rebate primarily shift sale product high dollar million discount prime vendor medicaid program decrease sale pharmaceutical return primarily attributable high sale return result net sale discontinue product product conversion overall increase gross nutritional tonet sale adjustment primarily sale growth net sale increase manage care rebate principally shift sale healthcare product high discount partially offset decrease wic rebate net sale decline state wic contract total company recognize revenue sale substantially risk reward ownership transfer customer generally occur date shipment substantially risk reward ownership transfer company use consignment model recog nize revenue model company recognize revenue shipment product shipment product company bristolmyers squibb company annual reportthe follow table set forth activity end balance significant category grosstonet sale adjustment manage woman healthcare prime infant rebate vendor child charge wic contract medicaid cash sale dollar million back rebate discount rebate discount return adjustment total balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december company record charge million medicaid rebate relate sale prior period charge include million rebate claim prior year certain state primarily relation medicaid utilization oncology product previously report company revision result availability additional information addition company record million adjustment result lowerthan expect rebate foreign government significant revision estimate grosstonet sale adjustment pharmaceutical composition net increase pharmaceutical sale follow key pharmaceutical product sale represent total pharmaceutical sale respectively follow analysis change change foreign total change volume price exchange dollar million cardiovascular plavix worldwide pharmaceutical sale increase million pravachol favorable foreign exchange impact domestic sale remain avaproavalide constant million compare million domestic sale monopril negatively affect increase competition pravachol exclusivity coumadin loss paraplatinand glucophage franchise offset increase sale virology plavix new product include abilify reyatazand erbitux sustiva international sale increase million decrease reyataz exclude favorable foreign exchange impact primarily generic videxvidex competition pravacholand taxol partially offset launches zerit abilify reyatazand continue growth plavix avaproavalide infectious disease worldwide pharmaceutical sale increase mil cefzil lion exclude favorable foreign exchange impact domestic sale tequin increase million primarily increase sale oncology plavix pravachol abilify glucovance paraplatinand partly taxol impact sale workdown nonconsignment wholesaler paraplatin inventory launch reyatazin july partially offset decrease erbitux sale glucophage taxolprimarily generic competition affective psychiatric international sale increase million include disorder favorable foreign exchange impact primarily increase sale abilify total revenue pravachol taxol plavix avaproavalide analgesic products europe metabolic partially offset price decline principally germany italy glucovance glucophage glucophage change excess bristolmyer squibb company annual reportsale plavix platelet aggregation inhibitor sell company sale sustiva nonnucleoside reverse transcriptase inhibitor treat primarily increase include favorable foreign ment hiv increase include favorable foreign exchange exchange impact million primarily impact million prior year primarily increase strong prescription growth market sale demand high price sale increase million million increase include favorable foreign total prescription growth increase exchange impact million primarily strong pre international sale sustivaincrease include favorable scription growth plavix cardiovascular product eign exchange impact million drive increase sale launch alliance company sanofiaventis spain france italy sustivasale increase sanofi market exclusivity plavix expect expire million million primarily workdown statement exclusivity subject adverse wholesaler inventory quarter market exclusivity pro determination occur respect plavix patent litigation tection sustivais expect expire country additional information plavix patent litigation note legal company market sustivain japan proceeding contingency sale reyataz protease inhibitor treatment hiv sale pravachol hmg coa reductase inhibitor decrease launch quarter europe second include favorable foreign exchange impact million quarter million compare million domestic sale decrease million total pre reyatazhas achieve weekly new prescription share protease scription demand decrease international sale decrease includ inhibitor market approximately market exclusivity reyatazi e favorable foreign exchange impact million expect expire countries japan exclusivity loss select european market include germany sale pravacholincrease million sale videxvidex antiretroviral agent treatment hiv million primarily wholesaler workdown inventory increase decrease exclude favorable foreign exchange continue growth europe particularly france impact million videxvidex sale increase italy market exclusivity protection pravacholis expect expire april million million increase sale europe market exclusivity expire excep partially offset sale decline company license tion france sweden expiration occur august arrangement government videxvidex march respectively italy expiration occur term nonexclusive government method use january patent expire include earn pediatric exten sion japan countries sales avaproavalide angiotensin receptor blocker treatment license company nonexclusive allow com hypertension increase include favorable foreign exchange pany obtain license government receive approval impact million drive increase sale europe marketing respect videxvidex company patent cover strong prescription growth approximately sale increase ing reduce mass formulation videxvidex expire include favorable foreign exchange impact million japan patent apply type million primarily strong prescription growth reduce mass formulation specify patent reduce mass price increase avaproavalide cardiovascular product launch mulation exist currently issue patent covering videx alliance company sanofi market exclusivity formulation avaproavalide know aprovelkarvea expect expire country avaproavalide sales zeritan antiretroviral agent treatment hiv decrease currently market japan include favorable foreign exchange impact million primarily result continue decrease demand potential sale monopril second generation angiotensin convert enzyme adverse effect zeritsale decrease include favorable ace inhibitor treatment hypertension decrease include foreign exchange impact million million favorable foreign exchange impact million impact primarily result decrease demand potential adverse market exclusivity loss sale million increase effect market exclusivity protection zeritis expect expire include favorable foreign exchange impact million country japan result introduction brand generic product new government contract market exclusivity protection monoprilexpired sale cefzil antibiotic treatment mild moderately severe expire expect expire bacterial infection decrease include favorable foreign country monoprilis currently market japan exchange impact million primarily decrease domestic demand partially offset high international sale cefzilsale sale coumadin oral anticoagulant predominately patient increase million million market atrial fibrillation deep venous thrombosispulmonary embolism exclusivity expect expire decrease million compare sale expire japan increase generic competition sale increase million million market exclusivity coumadinexpire bristolmyers squibb company annual reporttequin antibiotic treatment respiratory tract infection extend pende patent sale million decrease compare sale term extension grant company right copromote sale increase million million tequin abilify european country united kingdom france seasonal product sale increase flu season sale germany spain act exclusive distributor product fluctuation strong flu season rest european union market exclusivity protection weak flu season basic patent expire abilify expect expire extend expect patent eligible statutory patent term exten pende supplemental protection certificate grant sion company right market abilify expire november puerto rico country company sale taxol company leading anticancer agent exclusive right market abilify june additional informa million compare million sale taxol tion revenue recognition abilify note alliance exclusively international increase decrease exclud investment ing favorable foreign exchange primarily result generic competition europe generic competition taxolin majority major european glucophage franchise sale decrease million com market begin second quarter increase second pare increase million million half taxolsale increase decrease exclud decrease sale primarily result increase generic ing favorable foreign exchange million million competition glucophage oral medication treatment non primarily generic competition partially offset strong insulin dependent type diabete experience sale decrease sale japan france market exclusivity protection taxolexpire million sale decrease million mil expect expire lion glucovance oral combination drug glucophage japan extend release tablet sale million mil lion respectively compare sale million sale paraplatin anticancer agent decrease include million respectively sale million million favorable foreign exchange impact million generic competi respectively market exclusivity protection expire march tion begin mid increase entry mul glucophage october glucophage january tiple generic competitor fourth quarter domestic sale paraplatin glucovance company market decrease million paraplatinsale increase product japan significant foreign exchange impact million mil lion primarily introduction new formulation instance basic exclusivity loss date indicate expi paraplatinin price increase market exclusivity protection ration date patent claim active ingredient drug paraplatinexpire october method drug approve indication instance japan basic exclusivity loss date indicate expiration date datum exclusivity period situation datum exclusivity patent protec erbitux injection combination irinotecan treatment tion competitor seek regulatory approval submit clinical patient epidermal growth factor receptor egfrexpresse trial datum obtain marketing approval company assess market metastatic colorectal cancer refractory irinotecanbase exclusivity period product casebycase basis length chemotherapy single agent treatment patient market exclusivity company product difficult predict egfrexpresse metastatic colorectal cancer intolerant certainty complex interaction patent regulatory irinotecanbase chemotherapy approve fda february form exclusivity factor assurance particu sale erbitux sell exclusively lar product enjoy market exclusivity period time million year end december patent relate company currently anticipate combination therapy erbitux expire company right follow table set forth comparison report net sale change market erbitux north america japan expire september estimate total prescription growth retail mail order company market erbitux country customer certain company pharmaceutical prescription prod uct estimate prescription growth amount base thirdparty datum provide ims health supplier market research pharmaceutical total revenue abilify primarily domestic alliance revenue industry significant portion company domestic pharmaceutical company share net sale copromotion country otsuka sale wholesaler change report net sale differ pharmaceutical ltd otsuka million compare prescription growth change net sale reflect underlie million million respectively contin prescriber demand ued growth prescription demand launch schizophrenia agent introduce united states november december achieve weekly new prescription share antipsychotic market european commission grant marketing authorization abilify june total revenue reach million public sale commence june september fda approve abilify treatment acute bipolar mania market exclusivity protection abilify expect expire bristolmyer squibb company annual report continue monitor paraplatinsale intention work change change change change change change saler inventory month hand ustotal total ustotal company maintain inventory management agreement ima net sale prescription net sale prescription net sale prescription wholesaler account nearly total gross sale pharmaceutical product current term ima plavix wholesaler provide company information respect inventory lev pravachol el product hand outmovement product avaproavalide inventory information receive wholesaler product record monopril keeping process exclude inventory hold intermediary coumadin sell retailer hospital company determine sustiva outmovement product period month videxvidex recent prior week outmovement product provide zerit wholesaler company determine month hand estimate cefzil factor historical sale wholesaler glucovance party market research datum relate prescription trend patient demand glucophage nutritional excess composition net increase nutritional sale follow reflect change net sale dollar term include change average selling price wholesaler buy pattern reflect change total prescription unit term base thirdparty datum analysis change total change volume price foreign exchange follow table set forth company key pharmaceutical product sell company pharmaceutical business pharmaceuticals businesss net sale applicable product year end december estimate number month hand applicable product wholesaler distribution channel key nutritional product line sale represent december total nutritional sale respectively follow dollar million net sale month hand change plavix dollar million pravachol avaproavalide infant formula abilify toddlerchildren paraplatin nutritional sustiva glucophage franchise worldwide nutritional sale decrease million reyataz exclude impact adult nutritional business divest coumadin quarter worldwide sale increase million tequin million zerit international sale exclude impact adult nutritional business videxvidex increase primarily increase sale infant formula children monopril nutritional product increase international sale primarily increase enfagrow toddler children nutritional product company determine month hand estimate divide increase enfamil company largestselle infant formula include estimate product wholesaler distribution channel favorable foreign exchange impact domestic sale exclude impact estimate outmovement product period adult nutritional business increase million week calculate describe factor influence million primarily increase sale enfamil company estimate include generic competition seasonality product nutritional sale million increase include wholesaler purchase light increase wholesale list price new product unfavorable impact foreign exchange international sale launch new warehouse opening wholesaler new customer stock increase include unfavorable foreign exchange impact ing wholesaler million million domestic sale increase paraplatinlost exclusivity october demand decrease million million worldwide infant formula sale significantly result estimate month hand great increase million primarily increase sale month value paraplatininventory month hand december enfamil international sale enfamilincrease million approximately million company plan million domestic sale enfamilincrease million million worldwide toddler chil drens nutritional sale increase include unfavorable foreign bristolmyer squibb company annual reportexchange impact million million result geographic area increase sale enfagrow primarily pacific region company product available country million world large market united states france japan spain germany italy canada company sale geographic area healthcare follow healthcare segment include convatec medical imaging change business consumer medicine united states japan com position net increase healthcare sale follow dollar million analysis change total change volume price foreign exchange united states total europe middle east africa total healthcare sale business key product year western end december follow hemisphere change total pacific total dollar million total convatec ostomy sale united states remain constant growth pre wound therapeutic scription demand key brand include plavix avaproavalide sustiva medical imaging new product include abilify reyatazand erbitux offset low cardiolite sale product result exclusivity loss monopril paraplatin consumer medicine glucophage franchise sale united states increase primarily increase sale plavix pravachol abilify glucovance increase convatec sale increase paraplatin sale increase partially offset continued volume increase foreign exchange partially offset impact generic competition united states glucophage decrease change sell price increase taxoland result loss exclusivity label change indicating result increase worldwide sale wound therapeutic product potential effect serzone increase include favorable foreign exchange impact sale europe middle east africa increase decrease million ostomy sale flat exclude increase exclude impact foreign exchange result sale decline foreign exchange impact increase convatec sale pravacholdue exclusivity loss select market include germany increase worldwide sale ostomy product taxol generic competition majority major million strong growth worldwide wound therapeutic product european market begin second quarter decrease increase million foreign exchange contribute sale sale offset increase sale plavix germany spain increase avaproavalide italy spain sustivain majority major market sale increase include increase foreign increase medical imaging sale increase exchange result sale growth pravacholin france taxolin france volume increase change sell price increase germany spain italy analgesics france plavix germany spain foreign exchange increase medical imaging sale avaproavalide italy sustivain spain primarily drive increase sale ofcardiolite increase sale western hemisphere country increase include partially change time revenue recognition result increase foreign exchange primarily increase sale plavix new distribution agreement enter january avaproavalide canada sale increase include decrease foreign exchange primarily increase sale plavix consumer medicine sale remain flat million compare canada decline million sale increase pacific region sale increase include increase foreign primarily drive high sale excedrin offset exchange result increase sale taxoland paraplatinin decrease sale japan primarily low sale bufferinand japan plavix avaproavalide australia sale increase overthecounter medicine sale decline include increase foreign exchange result increase distributor reduce inventory level desirable level sale taxolin japan increase sale enfagrowthroughout region bristolmyer squibb company annual reportexpense expense increase million million change primarily increase sale support abilify avapro avalide high pension cost high charge relate system infrastruc ture high insurance premium unfavorable foreign exchange impact dollar million principally relate euro cost product sell net sale advertising product promotion expenditure remain constant marketing sell billion compare increase investment abilify reyataz administrative plavix offset low spending inline nonexclusive product net sale advertising promotion expense increase million advertising million primarily result promotional support product promotion abilify reyatazlaunche plavix additional sup net sale port inline product unfavorable foreign exchange impact europe research development company investment research development total mil net sale lion increase increase acquire inprocess percentage sale compare research increase research development development expense primarily high spend new devel net sale opment project include investment latestage development include provision restructure muraglitazar dual ppar agonist diabete abatacept potential item net treatment rheumatoid arthritis baracludefor hepatitis invest net sale ment area biologic partially offset merck share codevelop litigation charge net ment cost relate muraglitazar research development cost net sale include million consist primarily upfront milestone payment equity net income million charge relate upfront payment license affiliate agreement million accelerate depreciation research net sale facility research development spend dedicate expense net pharmaceutical product increase pharmaceutical sale net sale compare decrease compare total expense net increase reflect company strategic focus critical disease net sale areasaffective psychiatric disorder alzheimersdementia atherosclero sisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid change excess arthritis relate disease solid organ transplant company cost product sell percentage sale increase focus research development activity fully realize year compare value research development pipeline new priority include increase primarily increase accelerate depreciation rebalancing drug discovery development increase support million million million increase product liability reserve company latestage development pipeline close unnecessary unfavorable impact pharmaceutical sale mix facility include devote great resource ensure success impact generic competition glucophage franchise ful nearterm product launch increase company effort paraplatinand launch low margin erbitux partially offset sale inlicense opportunity growth abilify reyataz plavix cost product sell include million commercial litigation expense million product million charge acquire inprocess research devel liability insurance recovery cost product sell include opment relate purchase acordis specialty fibre acordis million accelerate depreciation asset manufacturing facility ukbased company expect strengthen company leader north america expect closed end million ship position wound therapeutic charge relate acquire charge asset impairment restructuring expense cost prod inprocess research development million primarily relate uct sell include million reversal prior period reserve milestone payment imclone system incorporate imclone inventory writeoff relate cancel action erbitux million milestone payment imclone million expense acquire inprocess research development marketing sell administrative expense percentage sale quarter remain million record additional marketing equity investment eliminate income statement effect portion sell administrative expense increase million milestone payment company economic claim primarily increase sale marketing support new ownership interest imclone product include additional sale representative support abilify addition increase relate cost associate compli restructure program implement downsize realign ance sarbanesoxley act unfavorable foreign exchange streamline operation order increase productivity reduce operating drive strengthen euro marketing sell administrative expense rationalize company manufacture network research bristolmyers squibb company annual reportfacilitie sale marketing organization action primarily related busparand taxolsettlement additional informa restructuring program expect complete action tion litigation note legal proceeding contingency restructure program substantially complete action restructure program complete equity net income affiliate million compare december result action company expect million million respectively equity net future annual benefit earning continue operation minority income affiliate principally relate company joint venture interest income taxis approximately million million sanofi investment imclone increase equity million program respectively net income affiliate primarily reflect high net income sanofi additional information restructuring note restructure joint venture additional information equity net income affiliate item note alliance investment litigation charge net settlement income million expense net income million million mil compare million million mil lion respectively expense include net inter lion consist million relate private litigation govern e expense foreign exchange gain loss income thirdparty mental investigation relate wholesaler inventory issue accounting contract manufacture royalty income gain loss disposal matter million relate platinollitigation settlement mil property plant equipment favorability primarily lion relate pharmaceutical pricing sale practice high income thirdparty contract manufacturing low net interest company establish reserve liabilitie total mil expense low net foreign exchange loss decrease expense lion comprise million relation wholesaler inventory issue primarily net gain interest rate swap certain accounting matter million relation pharmaceu tical pricing sale marketing practice addition company year end december company record charge million litigation matter recognize record item affect comparability result period income million million income consist primarily mil present set forth follow table discussion lion income patent defense cost reimbursement million litiga item note alliance investment note restructure tion settlement income million settlement antitrust item note acquisition divestiture note litigation involve vitamin manufacturer charge million discontinue operation year end december provision acquire litigation cost process gain restructure settlement product research research sale expense expense dollar million sell development development business item net income net total litigation matter private litigation governmental investigation product liability pharmaceutical pricing sale litigation commercial litigation antitrust litigation product liability insurance recovery gain sale adult nutritional business accelerate depreciation downsize streamline worldwide operation upfront milestone payment acordis iprd writeoff income taxis item defer taxis anticipation repatriation foreign earning tax adjustment reduction net earning continue operation relate wholesaler inventory accounting matter consist million reserve record fourth quarter million disclose company second quarter amount incremental million record year bring total reserve million incremental million reserve record company year bring total reserve million bristolmyer squibb company annual reportyear end december provision litigation cost restructure settlement product research expense dollar million sell development item net income total litigation matter private litigation governmental investigation product liability pharmaceutical pricing sale litigation litigation settlement income upfront payment license agreement accelerate depreciation asset impairment charge termination benefit exit cost relocation retention change estimate income taxis item reduction net earning continue operation year end december provision acquire litigation cost process restructure settlement product research research expense asset expense dollar million sell development development item net income impairment income total litigation matter antitrust litigation commercial litigation litigation sale product right termination benefit exit cost acquire inprocess research development asset impairment charge income taxis item settlement prior year tax matter reduction net earning continue operation bristolmyer squibb company annual reportearning operate loss tax credit carryforward foreign net operating loss tax earning credit carryforward charitable contribution carryforward company continue operation currently believe state net defer tax asset state net operating minority interest loss tax credit carryforward foreign net operating loss tax credit income taxis change carryforward charitable contribution carryforward valuation allowance provide likely realize dollar million future pharmaceutical pharmaceutical nutritional earning minority interest income taxis million healthcare decrease million primarily drive gross margin erosion total segment generic competition product mix additional sale representative corporateother support abilify increase spending research development high total nonclinical grant litigation settlement income partially offset high sale earning minority interest income taxis earning continue operation minority interest million increase primarily increase income taxis decrease million million sale partially offset increase advertising product spend new contributing decrease increase cost product sell exist inline product result change product mix product lose exclusivity increase investment research development income expense nutritional affect comparability result discuss partially offset earning minority interest income taxis increase million high international sale net earning continue operation decrease million increase primarily increase million million basic earn global infant formula sale price increase infant formula line favorable ing share continue operation decrease manufacture variance tight operate expense management dilute earning share continue operation earning minority interest income taxis nutritional segment decrease increase million result increase sale enfamil earning continue operation minority interest income taxis increase million million healthcare increase primarily result increase sale charge million earning minority interest income taxis healthcare record litigation settlement asset impairment writeoff segment increase million million primarily inprocess research development increase partially offset sale growth convatec medical imaging business addi increase investment advertising promotion marketing selling tion favorable pricing product mix earning minority administrative expense earning continue operation increase interest income taxis segment decrease million million million basic primarily result unfavorable product mix inventory writeoff dilute earning share continue operation increase excedrinquicktab consumer medicine business respectively respectively effective income tax rate earning continue operation discontinue operation minority interest income taxis compare december company commit plan sell otn high effective tax rate attributable pri enter definitive sale agreement equity partner llc otn marily million charge estimate defer taxis take fourth report distinct operating segment transaction quarter anticipation repatriate approximately billion special expect complete half sale price equal dividend companys nonus subsidiary pursuant american million plus certain price adjustment base otns excess current job creation act ajca increase estimate contingent tax asset current liability close date sale result pretax matter compare charge relate establishment gain million subject certain price adjustment post valuation allowance certain charitable contribution carryforward closing matter gain sale otn recognize closing increase partially offset favorable resolution certain tax date discussion otn note discontinued operation refund claim increase foreign tax credit effect certain light follow amount related otn business segregate igation reserve nondeductible company estimate tax continue operation reflect discontinued operation cost relate dividend repatriation december base period present tax law effect estimate revise result additional guidance clarify language issue congress andor department treasury change companys factual assump tion occur increase effective tax rate effective tax rate primarily decrease effective tax rate benefit operation ireland puerto rico switzerland treatment provi sion certain litigation reserve nondeductible increase esti mate contingent tax matter compare company record valuation allowance certain state net defer tax asset state net bristolmyer squibb company annual reportdollar million authorization application baracludeto european medicine evaluation agency net sale august fda approve company supplemental new drug earning income taxis net earning discontinue operation application snda include new longterm virologic clinical datum bms study prescribing information relate sustivaefavirenz net earning discontinue operation million reflect new datum demonstrate longterm durability virologic response people statement earning primarily reflect reduction million live hiv naive protease inhibitor lamivudine tax contingency reserve relate spinoff zimmer holdings inc nonnucleoside reverse transcriptase inhibitor nnrti year treatment combination regimen contain sustiva development july fda approve company snda include new scien january company announce intends div tific datum dose package insert labeling relate reyataz canadian consumer medicine business company primary con snda reyatazlabele include datum indicate combination hiv sumer medicine brand canada excedrin keri choiceand treatment contain reyatazritonavir kaletra lopinavirritonavir abbott comtrex year end december sale consumer medicine laboratory inc similar primary efficacy outcome measurement brand canada total approximately million timeaveraged difference change baseline hiv rna level hiv company consumer medicine business japan asia pacific latin infect patient previously take antihiv medicine america europe middle east africa include divestiture june company otsuka announce european december company provide update rolling commission grant marketing authorization abilify antipsychotic med bla abatacept submit provision fdas continuous ication treatment schizophrenia otsuka pharmaceutical europe ltd marketing application pilot abatacept investigational biologic drug otsukas european hold company hold marketing authorization treatment rheumatoid arthritis development program grant abilify europe company otsuka currently copromote abilify fast track status fda complete nonclinical clinical section united kingdom germany copromote france spain bla submit fda remain section addition company exclusive right sell abilify number expect submit early year country europe fda approve abilify treat december company somerset pharmaceuticals inc ment acute bipolar mania september december somerset joint venture mylan laboratories inc watson company otsuka receive approval fda oral solution pharmaceuticals inc enter agreement commercialization mulation abilify oral solution available pharmacy distribution somerset emsam selegiline transdermal system investiga february tional monoamine oxidase inhibitor administer transdermal patch company enter worldwide codevelopment acute maintenance treatment patient major depressive disorder cocommercialization agreement solvay pharmaceutical solvay code somerset receive approvable letter fda emsam february velop copromote investigational compound slv currently approve fda emsam transdermal treat phase development potential use treat obesity ment major depressive disorder metabolic disorder company elect develop market december company corgentech inc announce topline additional investigational compound select solvay pool eligible result phase clinical trial edifoligide decoy compound company pay solvay upfront milestone payment trial involve patient undergo peripheral artery vein graft primary million july expense research development secondary endpoint fail benefit edifoligidetreate group milestone payment expect successful compare placebo group define rate vein graft failure outcome certain development regulatory stage month follow surgery edifoligide investigational product pre april company enter collaboration agreement vent vein graft failure coronary peripheral artery merck worldwide codevelopment copromotion muraglitazar december company gilead sciences inc gilead enter company dual ppar peroxisome proliferator activate receptor agonist cur joint venture develop commercialize fixeddose combination rently phase iii clinical development use treat type diabetes company sustivaand gilead truvada emtricitabine tenofovir nda muraglitazar submit fda december reg disoproxil fumarate united states approve new product ulatory approval term agreement company receive complete highly active antiretroviral therapy haart treatment million upfront payment receive additional regimen hiv available fixeddose combination take daily million milestone payment january filing nda november company medarex inc medarex enter company entitle receive million additional payment worldwide collaboration develop commercialize mdx fully human achievement certain regulatory milestone company merck antibody investigational product target ctla receptor mdx jointly develop clinical marketing strategy muraglitazar share develop medarex currently phase iii clinical development equally future development commercialization cost copromote treatment metastatic melanoma collaboration agreement effec product physicians global basis merck receive payment tive january time company cash payment base net sale level million medarex expense research development april company pierre fabre mdicament pierre additional million equity investment medarex fabre enter agreement develop commercialize javlor september company complete submission nda vinflunine novel investigational anticancer agent javlor currently fda baraclude investigational antiviral agent development phase iii clinical trial europe treatment bladder nonsmall treatment chronic hepatitis addition fda grant company cell lung cancer phase clinical trial breast ovarian cancer priority review baraclude company submit marketing term agreement company receive exclusive license bristolmyer squibb company annual reportjavlor united states canada japan korea select southeast asian repatriate united states company determine earning market pierre fabre responsible development marketing remit foreseeable future additional tax provision javlor country include europe agreement require complexity tax law assumption company expensed upfront milestone payment million practicable estimate amount income taxis potential additional million milestone payment provide time ajca president bush sign law october pro april company announce completion acquisition vide temporary percent dividendsreceive deduction certain cash acordis million acordi privately hold company base distribution earning foreign subsidiary deduction result license patent right supply material convatec wound federal tax rate approximately repatriate earning assum therapeutic line acquire business incorporate e marginal federal tax rate earning qualify company convatec division acquisition enable convatec deduction repatriate earning reinveste united states pur strengthen position field wound care management continue suant domestic reinvestment plan approve company chief execu provide new treatment option patient acute chronic wound care tive officer subsequently board director january needs note acquisition divestiture department treasury issue guideline permit investment march company announce medical imaging business plan company expect meet requirement criterion qualify enter agreement kereo inc kereo development deduction provision ajca require clarifica commercialization novel molecular imaging agent term tion address coming month treasury congress agreement company work develop molecular imaging company estimate tax cost relate repatriation december agent cardiovascular disease cancer kereo core technology base tax law effect extent tax law medical imaging obtain exclusive worldwide right develop com guidance change estimate revise company estimate mercialize select cardiovascular molecular imaging agent magnetic reso revise result change companys factual assump nance image mri kereo obtain exclusive worldwide right use tion occur family medical imaging target molecule kereo core technology cash cash equivalent december primarily consist develop commercialize molecular cancer imaging agent target dollar denominate bank deposit original maturity month therapeutic include kereo lead candidate early mri detection marketable security december primarily consist tumor dollar denominate float rate instrument aaaaaa credit rating february fda approve bla erbitux anticancer nature instrument company consider reasonable agent company develop partnership imclone erbitux expect fair market value significantly impact injection use combination irinotecan treatment patient change interest rate liquidate cash short notice egfrexpresse metastatic colorectal cancer refractory average interest yield cash cash equivalent irinotecanbase chemotherapy use single agent treatment december respectively interest yield marketable patient egfrexpresse metastatic colorectal cancer intoler security average respectively ant irinotecanbase chemotherapy accordance agreement longterm debt december denominate primarily company pay imclone million march milestone payment dollar include japanese yen debt million longterm debt approval erbitux fda fda approve imclone remain constant billion december majority chemistry manufacturing control supplemental bla licensure company debt fix rate company enter manufacturing facility erbitux june fix float interest rate swap billion longterm debt interest expense net interest swap gain million million financial position liquidity capital resource million respectively increase interest expense cash cash equivalent marketable security total approximately primarily increase shortterm borrowing billion december compare billion december high interest rate decrease drive company continue maintain high level work capital net gain interest rate swap commercial paper outstanding billion december increase billion december billion average interest rate december company expect cash generate commercial paper outstanding december operation borrowing capital market sufficiently average interest rate year end december cover cash need work capital capital expenditure milestone payment international shortterm borrowing respectively dividend pay united states cash cash equivalent marketable current installment longterm debt respectively security conversion workingcapital item borrowing december company replace prior billion revolve credit expect fund nearterm operation facility new billion fiveyear revolve credit facility syndicate december company approximately billion lender extendable anniversary date consent undistribute earning foreign subsidiary company accrue provi lender availability facility subject company ability sion million estimate deferred taxis fourth quarter time borrowing meet certain condition include financial covenant expect pay anticipation repatriate approxi net debt capital exceed facility contain mately billion undistributed earning pursuant ajca material adverse change representation company business condition taxis provide balance undistribute earning approxi borrow december company ratio consoli mately billion company invest expect invest date net debt consolidate capital compliance undistribute earning permanently offshore future earning covenant inception facility change public credit rating affect availability credit facility borrowing bristolmyers squibb company annual reportstande revolve credit facility december proceed receive issuance convertible debt company unused shortterm line credit foreign bank cash provide operation borrowing primarily million million december respectively past year pay dividend billion company april moodys investors service moodys lower company invest billion past year capital expansion improve longterm credit rating march affirm prime plant efficiency maintain superior research facility shortterm credit rating company july standard poor company repurchase common lower longterm credit rating company affirm stock company repurchase million share common stock cost shortterm rating march place longterm short million bring total share acquire share term rating company watch negative implication august repurchase program inception million share share repurchase downgrade shortterm credit rating company program authorize company purchase common stock time time longterm credit rating company moodys sps long open market private transaction market condition permit term credit rating remain negative outlook program intend reduce increase share outstanding follow discussion work capital cash flow activity option exercise obtain share general corporate purpose dividend declare common share dollar million december company declare quarterly dividend work capital common share indicate dividend year cash flow share dividend decision quarterly basis board operating activity director invest activity companys financial condition liquidity affect obliga financing activity tion milestone onetime payment outcome pende litigation investigation include challenge plavix increase work capital million primarily patent information note alliance investment increase receivable result high sale high foreign note legal proceeding contingency hold taxis expect refunded high inventory result new product introduction high demand exist key brand partially offset high account payable high purchasing activity contractual obligation high accrue expense rebate return mainly increase payment period company contractual obligation royalty higher unrealized loss derivative medicaid rebate december follow obligation expire period net cash provide operating activity billion bil later dollar million total year lion billion decrease net cash provide operating activity mainly attributable low earning shortterm high usage work capital significant change operate borrowing longterm debt asset liabilitie million increase operating lease inventory primarily introduction new product include purchase obligation reyatazand erbitux high demand key brand include plavix standby letter avaproavalide sustiva million decrease defer revenue credit consign inventory workdown consignment inventory liability million decrease account payable accrue total expense include advertising promotion defer revenue abilify longterm debt obligation include shortterm borrowing company milestone payment increase primarily consolidated balance sheet december balance represent income tax payment relate gain arise sale stand nominal longterm debt value contractual obligation table exclude clairol business increase earning high rate decrease defer interest payment obligation revenue consign inventory workdown consignment addition company commit potential inventory high account payable accrue expense partially offset future milestone payment thirdpartie inlicense develop reduction account receivable increase litigation settlement payment ment program payment agreement generally payable achievement certain developmental regulatory andor net cash investing activity billion compare commercial milestone achievement milestone nei billion billion decrease net cash ther probable reasonably estimable contingency invest activity mainly attributable million cash proceed record company consolidate balance sheet sale company adult nutritional business low purchase discussion contractual obligation reference note marketable security million low capital spending partially shortterm borrowing longterm debt note financial instrument offset milestone payment million imclone million pay note lease note pension postretirement benefit plan ment acordis acquisition increase purchase trademark patent license restatement previously issue financial statement previously disclose company experience substantial buildup net cash financing activitie billion billion wholesaler inventory pharmaceutical business decrease mainly attribut buildup primarily sale incentive offer company able increase shortterm borrowing partially offset wholesaler incentive generally offer end bristolmyer squibb company annual reportquarter order incentivize wholesaler purchase product sec consent order sufficient meet company quarterly sale projection establish previously disclose august company enter final company senior management april company disclose settlement sec concluding investigation concern certain substantial buildup develop subsequently undertake plan work saler inventory accounting matter settlement reach orderly fashion wholesaler inventory level reduce consent copy attach exhibit company quar sale company wholesaler relative terly report form period end september sale wholesaler customer reduce inventory consent company agree admit deny liability company product hold wholesaler violate certain provision security law company agree october base review consideration previously establish million fund class shareholder distribute disclose buildup wholesaler inventory companys pharmaceu court supervision million fund include million tical business incentive offer certain wholesaler advice civil penalty distribute certain company shareholder plan pricewaterhousecooper llp pwc independent register public distribution establish sec accounting firm company determine require restate term consent company agree subject certain sale earning correct error time revenue recognition certain define exception limit sale product sell direct customer sale large wholesaler pharmaceutical busi include wholesaler distributor hospital retail outlet pharmacy ness company determine sale account government purchaser base expect demand amount consignment model base relationship exceed approximately month inventory hand make nature incentive offer wholesaler timely public disclosure change practice company estab inventory hold wholesaler lishe companywide policy limit sale direct customer purpose follow determination company determine comply consent policy include adoption pro correct historical accounting policy conform account cedure monitor limit sale direct customer accordance generally accept accounting principle gaap know error term consent procedure include governance process escalate application gaap previously record appropriate management level potential question concern case company believe error material compliance policy timely resolution question concern company consolidate financial statement addition restate addition compliance policy monitor regular basis ment process company investigate accounting practice area company maintain inventory management agreement ima involve significant judgment determine restate additional item pharmaceutical wholesaler account nearly respect company conclude error application total gross sale pharmaceutical product current term gaap include revision inappropriate accounting ima wholesaler provide company information march company complete restatement financial state inventory level product hand outmovement prod ment item restate financial statement year uct information receive wholesaler product end december restatement recordkeeping process exclude inventory hold intermediary complete restatement company continue identify sell retailer hospital company determine implement action improve effectiveness disclosure control movement product period onemonth recent procedure internal control financial reporting connection prior week outmovement product provide effort company substantially strengthen organization saler company determine month hand estimate personnel senior financial control function adopt pharmaceutical business factor historical sale rigorous policy procedure respect balance sheet review wholesaler thirdparty market research datum relate prescrip process iii focus internal audit function financial reporting control tion trend patient demand engage consultant assist evaluation documentation cer contrast company pharmaceutical business outside tain financial reporting disclosure process company united states nutritionals healthcare business unit particular respect design standard operating procedure imple world company significantly direct customer limit information menting tool ensure disclosure issue effectively identify man direct customer product level inventory correspond outmovement age control globally engage consultant assist information reliability thirdparty demand information avail company personnel conduct comprehensive detailed review cer able vary widely accordingly company rely variety method tain company tax reporting account particular respect estimate direct customer product level inventory calculate month develop effective process establish monitor defer hand business unit company expect complete analysis income taxis valuation allowance company annual effective tax direct customer inventory level business quarter rate addition request company audit committee inde provide additional disclosure information respect direct cus pendent register public accounting firm perform extensive proce tomer inventory level company continue enhance meth dure respect company interim financial information od estimate direct customer product level inventory month hand base auditor assessment company risk profile business unit take account complexity describe expand scope fieldwork perform certain area company continue disclose key pharmaceutical connection audit company action contribute product sell pharmaceutical business net sale significantly company identify additional error relate prior peri ods reflect restatement march company cor recte error restate financial statement year end december bristolmyers squibb company annual reportand estimate number month hand wholesaler distribu december fasb issue final staff position fsp tion channel end immediately precede quarter application sfas accounting income taxis tax end applicable quarter quarterly annual report form deduction qualified production activity provide american job business unit company expect disclose creation act effect adoption fsp mate quarterly basis key product level inventory information require rial company consolidate financial statement note estimate month hand direct customer distribution nonus accounting policiesincome taxis pharmaceutical business available prior time company december fasb issue fas exchange nonmonetary require file quarterly report form accordingly company asset provision statement effective nonmonetary asset expect disclose information website approximately day exchange occur fiscal period begin june provi end quarter addition forego quarterly disclosure sion statement apply prospectively eliminate company include forego information business unit exception fair value measurement nonmonetary exchange similar quarter annual report productive asset paragraph apb opinion accounting company believe abovedescribe procedure provide reason nonmonetary transaction replace exception exchange able basis ensure compliance consent order provide sufficient commercial substance adoption account pro information comply disclosure requirement nouncement expect material effect consolidated finan company agree consent certain measure cial statement implement implement include establish formal review november fasb issue sfas inventory costsan certification process annual quarterly report file sec amendment arb chapter standard require abnormal establish business risk disclosure group retain outside amount idle facility relate expense recognize current period consultant comprehensively study help reengineer company charge require allocation fix production overhead account financial reporting process publicly disclose sale cost conversion base normal capacity production facility incentive offer direct customer purpose induce sfas effective inventory cost incur fiscal year begin purchase product excess expect demand ensure ning june company evaluate impact state company budget process give appropriate weight input come ment financial position result operation come june fasb issue fsp accounting disclosure adequately document process requirement relate medicare prescription drug improvement company agree consent retain independent adviser modernization act medicare act medicare act introduce date company year end file prescription drug benefit medicare federal subsidy spon sec consent define certain power responsibility sors retiree health care benefit plan provide benefit independent adviser consent include process independent adviser actuarially equivalent medicare fsp require effect recommendation company compliance applicable new law account sfas employer account federal security law corporate obligation company agree postretirement benefit pension company adopt fsp consent adopt independent adviser recommendation compli quarter retroactive january ance applicable federal security law corporate obligation reduction net periodic benefit cost benefit million settlement resolve ongoing investigation sec base remeasurement accumulate postretirement benefit obli activity certain current member company manage gation january effect adoption fsp ment connection wholesaler inventory issue accounting material company consolidate financial statement note matter investigation ongoing addition investigation pension postretirement benefit plan attorney office district new jersey concern inventory march emerge issue task force eitf reach consensus accounting matter cover company settlement sec con issue participate security twoclass method tinue company continue cooperate investigation fas require use twoclass method computing earn ing share enterprise participate security multiple recently issue accounting standard class common stock consensus effective fiscal period begin december financial accounting standard board fasb ne march adoption eitf affect issue revise sfas sfas rsharebase payment company consolidate financial statement standard eliminate ability account sharebase compensation trans december fasb revised interpretation consolidation action intrinsic valuebase method accounting principle variable interest entitiesfin fin require variable interest entity board opinion apb accounting stock issue employee consolidated company company subject majority risk require instead transaction account fairvalue loss variable interest entitys activity entitle receive majority base method sfas effective financial statement issue entitys residual return fin require disclosure vari interim period begin june currently company able interest entity company require consolidate disclose pro forma net income relate pro forma income share significant variable interest consolidation requirement fin information accordance sfas accounting stockbase revise apply immediately variable interest entity create january compensation sfas accounting stockbase compensation exist entity fiscal year interim period end cost transition disclosure company evaluate impact march certain disclosure requirement apply finan statement material impact result operation cial statement issue january regardless variable interest entity establish accounting pronouncement material effect consolidated financial statement bristolmyers squibb company annual reportcritical accounting policy discussion revenue recognition note accounting policy company prepare financial statement conformity account revenue recognition sale rebate return accrual note ing principle generally accept united states preparation finan consignment cial statement conformity gaap require use estimate assumption affect report amount asset liability include grosstonet sale adjustment disclosure contingent asset contingent liability date company follow significant category grosstonet sale financial statement report amount revenue expense adjustment impact company reportable segment prime reporting period company critical accounting policy vendor chargeback wic rebate manage health care rebate important company financial condition result contract discount medicaid rebate cash discount sale return operation require difficult subjective complex judgment adjustment involve significant estimate judgment management application result need require company use information external source company estimate effect matter inherently uncertain account grosstonet sale adjustment accordance eitf uncertainty factor surround estimate judgment issue account consideration give vendor customer preparation consolidated financial statement actual result include reseller vendor product sfas revenue vary estimate recognition right return exist sfas applicable net company believe follow discussion represent critical sale section reconciliation companys gross sale net sale accounting policy management company independent register significant category grosstonet sale adjustment public accounting firm discuss company critical accounting poli cie audit committee board director prime vendor chargeback company business participate prime vendor programs revenue recognition government entity significant department company recognize revenue accordance sab defense department veteran affair party revenue recognition financial statement amend sab pricing product extend wholesaler list price par revenue recognition company accounting policy revenue recogni ticipate entity entity purchase product wholesaler tion substantial impact report result rely certain esti low prime vendor price wholesaler charge difference mate require difficult subjective complex judgment acquisition cost low prime vendor price management company recognize revenue sale substantially company company account prime vendor chargeback reduc risk reward ownership transfer customer ing account receivable equal company estimate generally occur date shipment exception describe chargeback claim attributable sale company determine esti previous year certain transaction company mate prime vendor chargeback primarily base historical experi pharmaceutical wholesaler account consignment ence prime vendor chargebacks current contract price model case sale wholesaler result incentive prime vendor program company consider prime vendor excess wholesaler ordinary course business inventory level payment level inventory distribution channel company time understanding agreement course deal con claim processing time lag adjust reduction account receivable sistent business practice company extend incentive base periodically quarter reflect actual experience level excess inventory connection future purchase time incentive cover substantially vary directly wic rebate wholesaler cost carry inventory excess wholesaler ordinary company nutritional business participate competitive bid course business inventory level substantially risk reward de basis nutrition program sponsor state tribal government ership transfer shipment accordingly sale commonwealth puerto rico territory guam woman infant account consignment model determination child wic program company reimburse sale wholesaler meet forego criterion involve evaluation vari entity difference wholesaler list price contract price ety factor number complex judgment consignment eligible product company account wic rebate establish model company recognize revenue shipment product accrual equal company estimate wic rebate shipment product company invoice wholesaler claim attributable sale company determine estimate record defer revenue gross invoice sale price classify inven wic rebate accrual primarily base historical experience wic tory hold wholesaler consignment inventory company cost rebate current contract price wic program company inventory company recognize revenue net gross net consider level inventory distribution channel new wic contract sale adjustment discuss involve significant estimate terminate wic contract change exist wic contract wic par judgment consignment inventory long subject ticipation adjust accrual periodically quarter incentive arrangement describe later inven reflect actual experience tory sell wholesaler customer fifo basis case new product product introduction manage health care rebate contract discount extension exist line product company determine company offer rebate discount manage health care organi product similar therapeutic category company zation globally contract counterpartie hos reliably estimate expect return new product company pital group purchasing organization company account defer recognition revenue right return long exist manage health care rebate contract discount establish company develop sufficient historical experience estimate sale return accrual equal company estimate manage health bristolmyer squibb company annual reportcare rebate contract discount attributable sale adjust sale return accrual take account historical experience company determine estimate manage health care rebate company return good policy shelf life company prod contract discount accrual primarily base historical experience uct ranges average approximately month situ rebate discount current contract price ations company aware product distribution channel company consider sale performance product subject manage near expiration date company analyze situation health care rebate contract discount level inventory analysis indicate sale return large expect distribution channel adjust accrual periodically company adjust sale return accrual taking account historical quarter reflect actual experience experience company return good policy level inventory distribution channel medicaid rebate event product recall product discontinuance company company business participate state governmentmanage consider reason impact action adjust sale medicaid program certain qualify federal state return accrual appropriate taking account historical experience lev government program discount rebate provide partic el inventory distribution channel product discontinuance ipate state local government entity discount rebate provide estimate continue demand program include company medicaid company consider price change competitive product rebate accrual consider medicaid rebates purpose introduction generic product introduction competitive new discussion company account medicaid rebate establish product company generally believe factor impact accrual equal company estimate medicaid rebate sale return base historical experience company return claim attributable sale company determine estimate good policy medicaid rebate accrual primarily base historical experience return new product significantly difficult company medicaid rebate expansion prospective basis par assess company determines estimate sale return accrual pri ticipation nonmandatory aspect qualify federal state marily base historical sale return experience similar product government program legal interpretation applicable law relate line product medicaid qualify federal state government program similar therapeutic category limit circumstance new prod new information change medicaid program regulation uct extension exist line product company guideline impact rebate company historical experience product similar therapeutic category consider outstanding medicaid claims medicaid payment level company reliably estimate expect return new inventory distribution channel adjust accrual periodically product company defer recognition revenue right return quarter reflect actual experience long exist company develop sufficient historical experience estimate sale return company consider shelf cash discount life new product determine believe adjustment certain country company offer cash discount sale return accrual appropriate shelf life connection new generally approximately sale price incentive prompt product tend short shelf life establish product payment company account cash discount reduce account company develop optimal manufacturing receivable discount company consider pay process new product lengthen shelf life ment performance adjust accrual reflect actual experience launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand sale return case company assess reduce shelf life level company account sale return accordance sfas inventory distribution channel project demand determine establish accrual equal company estimate believe adjustment sale return accrual appropriate sale record related product expect return provision sale return million adjustment million million respectively respectively addition significant grosstonet sale adjustment describe gross sale company make grosstonet sale adjustment example return establish product company determine estimate company offer sale discount significantly nonus business sale return accrual primarily base historical experience offer consumer coupon rebate significantly sale return consider factor impact sale return nutritional consumer medicine pharmaceutical business addi factor include level inventory distribution channel esti tion number country outside include major european coun mate shelf life product recall product discontinuance price change try company provide rebate government entity company competitive product introduction generic product introduction generally account grosstonet adjustment establish competitive new product company consider factor accrual equal company estimate adjustment attribut adjust accrual periodically quarter reflect actual able sale company generally determine estimate accrual experience grosstonet sale adjustment primarily base historical experience company consider level inventory distribution channel performance commitment government entity relevant factor determine believe adjustment sale return accrual include level inventory distribution channel case adjust appropriate example level inventory distribution channel accrual periodically quarter reflect actual experience increase company analyze reason increase rea son indicate sale return large expect company bristolmyer squibb company annual reportuse information external source company provide comprehensive medical group life benefit company use information external source estimate signifi substantially retiree elect participate company compre grosstonet sale adjustment company estimate inventory hensive medical group life plan asset allocation postretire wholesaler defer revenue consign inventory base ment plan identical asset allocation describe project prescription demandbase sale product historical inven define benefit pension plan tory experience company analysis thirdparty information include write oral information obtain certain wholesaler accrual account significant assumption respect inventory level sellthrough customer thirdparty consistent requirement sfas employer accounting market research datum company internal information inventory pensionsthe company account pension benefit accrual information receive wholesaler product recordkeeping method recognize pension expense payment benefit process exclude inventory hold intermediary sell retiree accrual method accounting pension benefit necessarily retailer hospital company receive information im require actuarial assumption concern future event determine health supplier market research pharmaceutical industry time benefit payment use project prescription demandbase sale company key assumption calculate cost pension ben pharmaceutical product company use information external efit discount rate rate compensation increase expect source identify prescription trend patient demand average sell longterm rate return plan asset company consultation price company estimate subject inherent limitation estimate actuary evaluate key actuarial assumption assumption rely thirdparty information certain thirdparty information calculate cost pension benefit retirement turnover mor form estimate reflect limitation include lag tality rate base expectation actual experience appropriate date thirdparty information generate date determine assumption december year calculate liabil company receive thirdparty information ity information date pension expense follow year depend assumption pension expense vary retirement benefit range outcome material effect report earning addition company pension plan postretirement benefit plan assumption materially affect accumulate benefit obligation account actuarial valuation require sfas employer future cash fund actual result give year differ esti accounting pensionsand sfas employer account mate economic factor postretirement benefit pensionsthe company consider assume discount rate company determine future accounting retirement plan critical management require pension obligation plan base index aarated corpo significant subjective judgment number actuarial assump rate bond indice high quality corporate bond select reflect tion include discount rate salary growth longterm return plan asset weightedaverage remain period benefit payment assume rate retirement turnover health care cost trend rate mortality rate depend compensation increase company determine future pension assumption estimate pension postretirement bene obligation reflect estimate change actual future compensation lev fit expense vary range outcome material effect el general price level productivity seniority factor report earning addition assumption materially affect accumu net pension expense company define benefit pension late benefit obligation future cash funding plan include earning minority interest income taxis million compare million plan description plan pension expense determine company certain subsidiary define benefit pension assume discount rate assume rate compensation increase plan define contribution plan regular fulltime employee princi present value benefit obligation december pal define benefit pension plan bristolmyers squibb retirement income plan determine assumed discount rate plan principal define contribution plan bristolmyer squibb salary increase rate assume discount rate determine saving investment program plan pension expense reduce expense approximately total company define benefit pension plan asset increase approximately million assumed rate liability hold plan asset plan hold compensation increase determine plan pension expense single trust common asset allocation specify reduce expense decrease reference section total company plan plan approximately million assumed discount rate determine international plan accumulate benefit obligation december reduce benefit company define benefit pension plan base pri accumulate benefit obligation increase marily year credit service participant compensation asset million company define benefit plan consist primarily equity fix plan pension expense determine income security december fair market value plan asset expect longterm rate return plan asset expect longterm rate company define benefit plan increase million return plan asset determine plan pension expense million december plan asset allocate reduce expense increase equity security compare end fix million income security compare end private equity investment compare end bristol myers squibb common stock represent asset plan end bristolmyer squibb company annual reportactual rate return earn plan asset year tion change assume discount rate difference follow actual expect return plan asset assumption change year return year return sfas require unrecognized net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value system atic rational manner year amortize pension income expense year extent unrecognize net actuar ial loss gain exceed great project benefit obligation marketrelated value plan asset begin year net discuss gaap provide difference expect gain loss recognize pension income expense prospectively actual return recognize average future service employee period approximate average remain service period active december company lower assume discount rate employee expect receive benefit plan approximately year plan maintain assume rate compensa extent offset loss gain subsequent year tion increase compensation assume increase scale december unrecognize net actuarial loss determine different rate different age rate disclose december base marketrelated value plan asset million single rate age produce exceed great project benefit obligation present value benefit obligation reduction discount rate market relate value plan asset million offset future effect increase present value benefit obligation accordingly unrecognize gain high discount rate higher expect return effect increase pension expense addition plan asset amortization unrecognized loss expect increase company revise base review experience assumption lump pension expense follow year approximately mil sum utilization revision effect increase present value lion year reflect high expense expect benefit obligation accordingly effect increase pension december unrecognize net actuarial loss determine base expense marketrelated value plan asset million follow year strong performance global equity market fall exceed great project benefit obligation market sharply decline cumulative relate value plan asset million reverse rise cumulative event fair market value pension plan asset particular plan company reduce expect rate return plan asset accumulate benefit obligation plan yearend gaap revision effect increa require additional minimum liability circumstance e pension expense reduction stockholder equity establishment intangible asset company expect net pension expense define benefit december fair market value company define benefit pension plan include earning minority interest income taxis pension plan asset million relate accumulate benefit approximately million high million obligation million company recognize additional mini reflect thing decrease assume discount rate mum liability million cumulatively million december company assume discount rate expect offset million charge comprehensive income longterm rate return plan asset calculate cost pension bene include stockholder equity million reduction intangible fit cost postretirement benefit plan case asset december fair market value company define discount rate december rate benefit pension plan asset million relate accumulate pension benefit versus respectively benefit obligation million company recognize additional postretirement benefit reflect short duration minimum liability million cumulatively million december postretirement liability offset million charge comprehensive income health care cost retiree population assume increase include stockholder equity trend expect increase year actual cost higher assume likely signifi plan funding upward pressure company expense retiree health care company fund policy define benefit plan contribute december president bush sign law medicare amount provide current service fund past service liability prescription drug improvement modernization act effect company contribute million million define benefit medicare act reflect net periodic postretirement benefit cost plan respectively reduction million accumulate postretirement benefit obligation discussion retirement benefit note pension december reduction million postretirement benefit plan delay recognition actuarial gain loss acquire inprocess research development december unrecognize net actuarial loss fair value inprocess research development acquire busi company define benefit plan million million ness combination determine independent appraisal base pre respectively base fair market value plan asset unrecognize ent value research project project cash flow income approach net actuarial loss reflect large steady reduction weight utilize consistent guidance practice aid issue average discount rate year american institute certify public accountant entitle asset acquire sfas provide delay recognition actuarial gain loss business combination research development activity include amount arise change estimate plan benefit obliga focus software electronic device pharmaceutical industry future bristolmyer squibb company annual reportcash flow predominately base net income forecast project discussion equity investment note accounting policy consistent historical pricing margin expense level similar prod investment note alliance investment uct revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life restructure research project underlie patent determine fair value downsize streamline operation rationalize manufacture facili research project expect revenue adjust technical risk com tie company periodically record restructuring charge result pletion result cash flow discount rate approximate company estimate judgment future plan company weight average cost capital include future termination benefit exit cost incur discussion acquire inprocess research development restructuring action place actual result vary esti note accounting policy acquire inprocess research development mate result adjustment earning discussion restructure note accounting policy impairment longlive asset restructuring note restructure item accordance sfas accounting impairment disposal longlive asset company periodically evaluate current fact contingency circumstance indicate carry value depreciable longlive normal course business company subject contingency asset hold recoverable circumstance legal proceeding claim arise business cover determined exist estimate undiscounted future cash flow produce wide range matter include government investigation shareholder law longlive asset appropriate grouping asset compare suit product environmental liability accordance sfas carrying value determine impairment exist asset deter accounting contingenciesthe company record accrual contin mine impair loss measure base difference gencie probable liability incur asset fair value carry value estimate asset fair value loss reasonably estimate base quote market price active market available quote mar discussion contingency note accounting policy ket price available estimate fair value base valua income taxis contingency note income taxis note legal tion technique include discount value estimate future cash flow proceeding contingency company report asset dispose low carrying value estimate net realizable value income taxis goodwill evaluate annually impairment accordance december company approximately billion sfas goodwill intangible assetssfas require undistributed earning foreign subsidiary company accrue provi goodwill test impairment twostep process step sion million estimate deferred taxis fourth quarter identify potential impairment second step measure anticipation repatriate approximately billion earning impairment loss goodwill deem impaired carry pursuant ajca taxis provide balance undistribute reporting unit goodwill exceed estimate fair value sfas earning approximately billion company invest expect require indefinitelive intangible asset test impairment invest undistribute earning permanently offshore future onestep process consist comparison fair value earning repatriate united states company deter carry value intangible asset intangible asset deem mine earning remit foreseeable future additional tax impair net book value exceed estimate fair value provision require complexity tax law estimate future cash flow base reasonable supportable assumption practicable estimate assumption projection require management judgment change amount income taxis provide key assumption company business prospect company evaluate need defer tax asset valuation change market condition result impairment charge allowance assess likely realize discussion impairment longlive asset note account defer tax asset future assessment valuation policy impairment longlive asset goodwill allowance require require significant judgment include forecast intangible asset future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning equity investment period assessment december company review equity investment impairment base company net defer tax asset million net valuation determination decline market value investment allowance million company carry value temporary making determi addition company conduct business country nation company consider apb opinion equity method world subject tax numerous jurisdiction result busi accounting investment common stockand relate interpretation ness activity company file significant number tax return set forth factor evaluate determine loss value subject audit tax authority tax audits complex tax recognize include company ability hold investment authority disagree treatment item report company market price market price fluctuation investment publicly require year resolve company record accrual trade share inability investee sustain earning capacity tax contingency relate potential audit exposure include lim justify carry investment company ite transfer price certain tax credit state foreign tax mat investment imclone subject accounting note alliance ter accrual base management judgment well estimate investment discussion company investment ultimate outcome tax audits actual audit result vary imclone estimate bristolmyer squibb company annual reportfor discussion income taxis note account policiesincome composition matter patent plavix expire currently taxis note income taxis subject litigation united states similar proceeding involve plavix institute outside united states company continue believe patent valid infringe alliance outlook ner patentholder sanofi vigorously pursue case possi previously disclose anticipate sale decline contin ble time reasonably assess outcome litigation ued exclusivity loss expect adverse determination litigation time potential offset growth sale company inline recently launch poten generic competition plavix generic competition occur tial new product period change product mix adversely company believe unlikely occur second half impact gross margin product lose expect company subsidiary subject number significant lose exclusivity generally high margin addition earning pende lawsuit claim proceeding investigation possible adversely affect company investment support introduction time reasonably assess final outcome investigation litiga new product development launch additional new compound tion management continue believe previously disclose base management current estimate growth company year aggregate impact current reserve inline recently launch product riskadjuste assessment legal matter affect company reasonably likely material potential new product launch company expect earning growth company result operation cash flow material resume company continue rationalize cost base line financial condition liquidity company expectation sev strategy increase sale marketing emphasis specialist eral year describe reflect potential impact litigation high value primary care physician company result operation previously disclose company experience substantial revenue loss year expiration market exclusivity protection cautionary factor affect future result certain product company expect substantial incremental rev annual report write oral statement company enue loss represent continue decline make time time contain certain forwardlooking statement revenue product decline revenue certain addi mean section securities act section tional product lose market exclusivity primarily security exchange act identify forwardlooke state company estimate reduction net sale range billion ment fact use word expect anticipate esti billion level product lose lose mate target project guidance intend plan believe exclusivity protection specifically monoprilin united word term similar meaning expression connection state canada europe glucophage glucovance united discussion future operate financial performance state cefzilin united states paraplatinin united states videx identify forwardlooke statement fact relate strictly united states taxolin europe pravacholin europe company historical current fact forwardlooke statement base cur expect substantial incremental revenue loss rent expectation involve inherent risk uncertainty include factor represent continue decline net sale product lose exclusivity delay divert change cause actual protection additional decline attributable prod come differ materially current expectation statement likely uct lose exclusivity protection primarily prod relate thing company goal plan projection uct year lose exclusivity protection include financial position result operation cash flow market posi glucophageglucovanceglucophage united states tion product development product approval sale effort expense perform taxolin europe japan pravacholin united states ance result current anticipate product outcome europe paraplatinin united states monopril contingency legal proceeding financial result base united states canada europe zeritin current expectation involve inherent risk uncertainty include united states europe cefzilin united internal external factor delay divert change states europe videxvidex year timing amount sale reduction exclusivity loss possible predict identify factor include realization particular period eventual level remain sale rev limited follow enue uncertain dependent level sale time exclusivity new government law regulation health care reform initia protection end time degree development generic competition tive united states state federal level country speed approval market entry impact factor change fda foreign regulatory approval process pravachol hmg coa reductase inhibitor statin net sale bil cause delay approve prevent approval new product iii lion company experience increase competition tax change phase tax benefit heretofore available pravacholfrom establish brand new entrant prescription united states certain foreign country new law regulation pravacholdecline compare product judicial decision affect pricing marketing jurisdiction begin lose exclusivity market anticipate loss change intellectual property law exclusivity april expect rate decline sale mar ket share accelerate increase competition establish competitive factor new product develop competitor brand new entrant low price superior performance feature company expectation future sale growth include substantial competitive company current product generic competition expect increase sale plavix net sale billion company product mature patent expire product iii techno currently company large product rank net sale logical advance patent attain competitor problem bristolmyer squibb company annual reportlicensor supplier distributor business combination change product mix affect margin company competitor major customer change companys structure operation revenue cost staff difficulty delay inherent product development manufacturing efficiency result acquisition divestiture merger alliance restruc sale product appear promise development fail turing strategic initiative reach market approve additional indication number reason include efficacy safety concern inability obtain nece economic factor company control change sary regulatory approval difficulty excessive cost manufacture business economic condition include limited change failure product achieve maintain commercial viability interest rate fluctuation foreign currency exchange rate iii seizure recall pharmaceutical product force closing manu facture plant failure obtain imposition limitation change business political economic condition political use loss patent intellectual property right failure social instability military armed conflict nationalization asset debt company vendor supplier comply current good payment moratorium restriction commerce actual threat manufacturing practice application regulation quality assur ene terrorist attack united states part world ance guideline lead temporary manufacturing shutdown relate military action product shortage delay product manufacture man ufacture distribution problem include change manufacture pro change accounting standard promulgate fasb sec duction site manufacturing capacity regulatory requirement aicpa require adjustment financial statement change type product produce biologic physical limita tion impact continuous supply capacity efficiency reliability security potential breakdown invasion destruction interruption information system legal difficulty include lawsuit claim proceeding investigation preclude delay commercialization product reliance company vendor partner party adversely affect operation profitability liquidity financial condition meet contractual regulatory obligation relation include intellectual property dispute adverse decision litigation arrangement company include product liability commercial case iii inability obtain adequate insurance respect type liability recall pharma result clinical study relate company competitor product ceutical product force closing manufacture plant failure fulfill obligation supply contract government company believe prudent plan assump customer result liability government investigation includ tion assurance give goal plan set forth forwardlook ing relate wholesaler inventory financial restatement product ing statement achieve reader caution place undue pricing promotion vii claim assert violation security antitrust reliance statement speak date federal state pricing law viii environmental health company undertake obligation release publicly revision forward safety matter tax liability assurance look statement result new information future event increase scope matter future lawsuit claim proceeding investigation material quantitative qualitative disclosure market risk increase pricing pressure worldwide include rule practice manage care group institutional governmental purchaser judi company expose market risk change currency cial decision governmental law regulation relate medicare exchange rate interest rate reduce risk company enter medicaid health care reform potential impact importation legisla certain derivative financial instrument available costeffective basis tive pharmaceutical reimbursement pricing general hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage fluctuation buy pattern inventory level major distributor natural offset derivative financial instrument speculative retail chain trade buyer result seasonality pric purpose gain loss hedge transaction offset gain e wholesaler buying decision include effect incentive offer loss underlying exposure hedge ineffective portion company wholesaler inventory management policy include hedge report earning occur workdown change wholesaler inventory level factor foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure great expect cost difficulty include unanticipated relation dollar euro japanese yen canadian dollar effect difficulty acquisition disposition event includ mexican peso ing obtain regulatory approval connection evolve business table summarize company outstanding foreign exchange strategy legal defense cost insurance expense settlement cost contract december fair value foreign exchange con risk adverse decision relate litigation tract base yearend currency rate blackschole model case option contract fair value option contract forward con change advertise promotional spend category tract view relation fair value underlie hedged spending affect sale transaction overall reduction exposure adverse fluctuation foreign currency exchange rate bristolmyers squibb company annual reporta hedge mark market incomeexpense notional weight fair value foreign exchange forward contract december dollar million average notional fair million million respectively currency rate strike price value maturity company use derivative instrument interest rate risk man agement policy derivative instrument include interest rate swap foreign exchange forward australian dollar subject fairvalue hedge accounting treatment british pound company execute fixedtofloate interest rate swap canadian dollar convert billion company fix rate debt pay euro variable rate debt year end december polish zloty company recognize net reduction interest expense swedish krona million reflect benefit lower float rate obtain swap swiss franc agreement sfas require revaluation fair value swap contract underlie debt hedge swap con option contract tract underlie debt revalue result increase japanese yen noncurrent asset million shortterm liabilitie million long total contract term debt million increase noncurrent asset longterm december company hold option forward exchange debt million december respectively swap con contract maturity date notional amount fair tract generally hold maturity speculative purpose value maturity date express table follow table summarize interest rate swap outstanding december notional notional variable fair value underlie rate year maturity million million dollar million debt receive maturity fair value interest rate contract swap associate month note libor swap associate month december company hold option contract aggre note libor gate notional fair value million million respectively option company right buy japanese yen specify swap associate month rate company hold forward contract aggregate notional note libor million fair value forward contract mil lion record current liability contract primarily relate swap associate month exposure euro canadian dollar australian dollar company obli note libor gate settle forward contract base specify contract rate swap associate month december balance defer net aftertax loss option note libor forward contract include accumulate comprehensive income million million estimate reclassify earning swap associate month month note libor year end december impact hedge ineffectiveness earning loss million additionally company use forward contract offset exposure certain currency asset liability december company hold interest rate swap contract forward contract designate hedge change notional value million fair value million fair value derivative recognize earning occur estimate change interest rate structure december company record loss million relate material impact company consolidate financial position result ward exchange contract qualify hedge accounting treatment operation cash flow december company hold option forward exchange company million million longterm debt contract aggregate notional fair value million standing december respectively note short million respectively contract primarily relate exposure term borrowing longterm debt note financial instrument euro japanese yen canadian dollar australian dollar additional information addition foreign exchange hedge contract note company maintain cash cash equivalent marketable security company use foreign exchange forward contract hedge foreign currency financial institution order limit exposure financial denominate monetary asset liability primary objective institution financial institution headquarter primarily north eign exchange forward contract protect dollar value foreign america europe currency denominate monetary asset liability effect volatility foreign exchange occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate japanese yen euro forward contract designate bristolmyer squibb company annual reportconsolidate statement earning year end december dollar million share datum earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure item net litigation charge net gain sale businessesproduct line asset impairment charge investment imclone equity net income affiliate expense net total expense earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation net earning net gain disposal net earning earning common share basic earning continue operation discontinue operation net earning net gain disposal net earning dilute earning continue operation discontinue operation net earning net gain disposal net earning average common share outstanding basic dilute dividend declare common share accompany note integral financial statement bristolmyers squibb company annual reportconsolidate statement comprehensive income retain earning dollar millions comprehensive income net earning comprehensive income foreign currency translation net tax benefit defer loss derivative qualify hedge net tax liability tax benefit minimum pension liability adjustment net tax benefit available sale security net tax liability total comprehensive income comprehensive income retain earning retain earning january net earning cash dividend declare zimmer common stock dividend retain earning december accompany note integral financial statement bristolmyers squibb company annual reportconsolidate balance sheet december dollar million asset current asset cash cash equivalent marketable security receivables net allowance inventory include consignment inventory defer income taxis net valuation allowance prepaid expense total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance asset total asset liability current liability shortterm borrowing account payable accrue expense accrue rebate return foreign income taxis payable dividend payable accrue litigation liability defer revenue consign inventory total current liability liabilitie longterm debt total liability commitment contingency stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share million issue million issue capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock million common share million total stockholder equity total liability stockholder equity accompany note integral financial statement bristolmyers squibb company annual reportconsolidate statement cash flow year end december dollar million cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax benefitexpense litigation settlement expense provision restructure item gain sale businessesproduct line include discontinue operation acquire inprocess research development loss gain disposal property plant equipment investment company undistribute earningslosse affiliate net unfunded pension expense impairment charge asset writeoff change operate asset liability receivables inventory prepaid expense asset defer revenue consign inventory litigation settlement payment account payable accrue expense product liability foreign income taxis payable liability net cash provide operating activity cash flow invest activity purchase net sale maturity marketable security addition property plant equipment capitalize software proceed disposal property plant equipment investment company proceed sale businessesproduct line imclone milestone payment purchase acordis specialty fibre purchase trademark patent license business investment company divestiture acquisition cost net cash investing activity cash flow financing activity shortterm borrowing net repayment longterm debt borrowing longterm debt repayment issuance common stock stock plan purchase treasury stock dividend pay net cash financing activity effect exchange rate cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral financial statement bristolmyers squibb company annual reportnote accounting policy million december respectively basis consolidation rebate accrual establish period relate revenue consolidated financial statement include account bristolmyer recognize result reduction sale establishment liability squibb company bms company bristolmyer squibb include accrue liability accrual record base esti control majority own subsidiary intercompany balance transac mate proportion record revenue result rebate return tion eliminate certain prior year amount reclassify prime vendor chargeback accrual establish similar manner conform current year presentation record reduction account receivable million million december respectively use estimate preparation financial statement conformity generally income taxis accept accounting principle gaap require use estimate provision income taxis determine asset lia assumption affect report amount asset liability dis bility approach accounting income taxis approach defer closure contingent asset contingent liability date financial taxis represent future tax consequence expect occur statement report amount revenue expense report amount asset liability recover pay provision reporting period significant assumption employ estimate income taxis represent income taxis pay payable current year determine value intangible asset restructure charge plus change defer taxis year defer taxis result accrual sale rebate return accrual legal contingency tax asset difference financial tax basis company asset tax liability estimate apply revenue recogni liability adjust change tax rate tax law change tion policy accounting retirement postretirement benefit include enact valuation allowance record reduce defer tax asset actuarial assumption actual result differ estimate result likely tax benefit realize december company approximately billion revenue recognition undistribute earning foreign subsidiary company accrue provi company recognize revenue substantially risk sion million estimate deferred taxis fourth quarter reward ownership transfer customer case certain anticipation repatriate approximately billion earning sale nutritional healthcare segment certain pursuant american job creation act ajca taxis nonus business pharmaceutical segment revenue recognize provide balance undistribute earning approximately billion date receipt purchaser revenues reduce time company invest expect invest undistributed earning sale reflect expect return estimate base historical experience permanently offshore future earning repatriate additionally provision time sale discount rebate united states company determine earning remit estimate sale allowance base historical experience update foreseeable future additional tax provision require com change fact circumstance appropriate provision plexitie tax law assumption record reduction revenue practicable estimate amount income taxis case sale wholesaler result incentive provide excess wholesaler ordinary course business inventory level ajca provide temporary percent dividend receive deduction time understanding agreement course deal con certain cash distribution earning foreign subsidiary deduc sistent business practice company extend incentive base tion result federal tax rate approximately repatriate level excess inventory connection future purchase time earning assume marginal federal tax rate earning incentive cover substantially vary directly qualify deduction repatriate earning reinveste wholesaler cost carry inventory excess wholesaler ordinary united states pursuant domestic reinvestment plan approve com course business inventory level substantially risk reward pany chief executive officer board director january ership transfer shipment accordingly sale department treasury issue guideline permit investment account consignment model determination plan company expect meet requirement criterion qualify sale wholesaler meet forego criterion involve evaluation vari deduction provision ajca require clarifica ety factor number complex judgment consignment tion address coming month treasury model company recognize revenue shipment product congress company estimate tax cost relate repatriation shipment product company invoice wholesaler december base tax law effect extent tax record defer revenue gross invoice sale price classifie inven law guidance change estimate revise company esti tory hold wholesaler consignment inventory company cost mate revise result change companys factual inventory company recognize revenue consignment assumption occur inventory long subject incentive arrangement later guidance financial accounting standard board fasb inventory sell wholesaler customer firstin staff position fsp application fasb statement fifo basis accounting income taxis tax deduction qualified production activity provide american job creation act deduction sale rebate return accrual treat special deduction describe statement financial medicaid rebate accrual million million december accounting standard sfas special deduction respectively woman infant child wic rebate affect defer tax asset liability exist enactment date accrual million million respectively manage health impact deduction report period deduc care rebate contractual discount accrual million tion claim company tax return bristolmyer squibb company annual reportthe company establish liability possible assessment tax authori capitalize software tie result know tax exposure amount represent reasonable certain cost obtain internal use software significant system project provision taxis ultimately expect pay need adjust capitalize amortize estimate useful life software time information know range year cost obtain software project significant expense incur capitalize software net accu cash cash equivalent mulate amortization include asset million mil cash equivalent primarily highly liquid investment original maturi lion december respectively amortization expense tie month time purchase record cost million million million year end december approximate fair value respectively marketable security investment company account marketable security accordance sfas january company adopt fasb interpretation fin account certain investment debt equity security interpretation consolidation variable interest entity interpretation company determine appropriate classification marketable security arb fin clarifie application accounting research bulletin availableforsale time purchase december arb consolidated financial statement certain entity company investment marketable security equity investor characteristic control financial interest report fair value unrealize gain loss report component sufficient equity risk entity finance activity accumulate comprehensive income loss stockholder equity additional subordinate financial support party entity amortize cost debt security adjust amortization premium know variable interest entity vie fasb issue revision fin accretion discount date purchase maturity amortization fin december fin effective interim period include interest income addition deduction coupon end march new exist vie adoption fin interest earn investment company follow investment man effect company financial statement ager method determine cost basis computing realize gain entity meet definition vie fin company loss sale availableforsale security average cost account entity provision arb consolidated method realize gain loss include income expense financial statement amend sfas consolidation majorityowne subsidiarieswhich require company consolidate inventory valuation majority own subsidiary ability exercise inventory generally state average cost excess market control company account own company ability exercise significant influence equity method capital asset depreciation accounting company share net income loss equity invest expenditure addition renewal improvement capitalize ment include equity net income affiliate consolidated state cost depreciation generally compute straightline method base ment earning company periodically review equity investment estimate useful life relate asset estimate useful life impairment adjust investment fair value decline major class depreciable asset year building year market value deem temporary machinery equipment fixture company periodically evaluate company record asset impairment charge million current event circumstance indicate carry value thantemporary decline market value imclone system incorporate depreciable asset recoverable imclone longterm investment security comprise marketable equity impairment longlive asset security security investment market value read effective january company adopt provision sfas ily available include asset marketable equity security classi accounting impairment longlive assetsthe adoption fie availableforsale report fair value fair value base quote sfas material effect consolidated financial state market price end report period security investment ment company sfas establish accounting impair market value readily available carry cost unrealize ment longlive tangible intangible asset goodwill gain loss report net relate tax effect component disposal segment business pursuant sfas company accumulate comprehensive income loss stockholder equity periodically evaluate current fact circumstance indicate sell time sale gain loss calculate specific identi carry value depreciable asset hold fication method recognize incomeexpense loss recoverable circumstance determine exist estimate recognize income decline market value deem undiscounted future cash flow produce longlived asset appro temporary priate group asset compare carry value determine impairment exist asset determine impair loss goodwill intangible asset measure base difference asset fair value car company adopt sfas goodwill intangible asset rye value estimate asset fair value base quote market january certain provision adopt july price active market available quote market price available respect amortization goodwill arise acquisition june estimate fair value base valuation technique include sfas address initial recognition measurement discount value estimate future cash flow company report intangible asset acquire outside business combination recognition asset dispose low carrying value estimate net measurement goodwill intangible asset subsequent realizable value bristolmyer squibb company annual reportacquisition sfas goodwill long amortize subject tion change fair value derivative record compre annual impairment test hensive income loss subsequently recognize consolidated accordance sfas goodwill test impairment statement earning hedge item affect earning cash flow adoption new standard annually sfas require classified consistent underlying hedged item purchase foreign goodwill test impairment twostep process step currency option entire change fair value include measurement identify potential impairment second step measure hedge effectiveness cash flow hedge ineffective portion change impairment loss goodwill deem impaired carry fair value cash flow hedge recognize charge credit reporting unit goodwill exceed estimate fair value earning company complete goodwill impairment assessment indicate company designate assign derivative hedge forecast impairment goodwill transaction specific asset specific liability hedge asset liabili intangible asset consist patent trademark technology tie sell extinguish forecast transaction hedge license amortize straightline basis useful life range long expect occur company immediately recognize gain year sfas require indefinitelive intangible asset loss designate hedge financial instrument consolidated state test impairment onestep process consist compari ment earning son fair value carry value intangible asset intangible asset deem impaired net book value exceed esti shipping handling cost mate fair value intangible asset evaluate impairment company typically charge customer shipping accordance sfas describe impairment longlive handling cost shipping handling cost charge include asset marketing sell administrative expense million million million respectively restructure downsize streamline operation rationalize manufacture facili advertising cost tie company periodically record restructuring charge result advertising cost expense incur advertising expense company estimate judgment future plan million million million respectively include future termination benefit exit cost approve incur actual result vary estimate result adjust milestone payment ment earning company time time enter strategic alliance party company right develop manufacture market andor product liability sell pharmaceutical product right own par accrual product liability record undiscounted basis tie result alliance company obligate pay probable liability incur liability ment alliance partner contingent achievement certain reasonably estimate base exist information accrual predetermine criterion milestone achieve prior marketing approval adjust periodically assessment effort progress additional informa product payment expense research development tion available receivables relate insurance thirdparty product approval additional milestone capitalize amortize recovery product liability record undiscounted basis cost product sell remain useful life asset capitalize probable recovery realize classified reduction liti milestone payment test recoverability event change gation charge consolidate statement earning circumstance indicate carrying amount recoverable contingency acquire inprocess research development normal course business company subject contingency fair value inprocess research development acquire busi legal proceeding claim arise business cover ness combination determine independent appraisal base wide range matter include product liability environmental present value research project project cash flow income liability tax matter accordance sfas accounting approach utilize consistent guidance practice aid asset contingency company record accrual contingency acquire business combination research development probable liability incur loss reason activity focus software electronic device pharmaceutical ably estimate discussion contingency reference note industry issue american institute certify public accountant income taxis note legal proceeding contingency future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar derivative financial instrument product revenue estimate base relevant market size growth derivative financial instrument company principally factor expect industry trend individual project life cycle life management interest rate foreign currency exposure company research project underlie patent determine fair value hold issue derivative financial instrument speculative purpose research project expect revenue adjust technical risk com company record derivative instrument balance sheet fair pletion result cash flow discount rate approximating value change derivative fair value recognize earning company weight average cost capital acquire inprocess specific hedge criterion meet derivative designate fair value research development expense incur underlying prod hedge change fair value derivative hedge item uct receive regulatory approval future alterna attributable hedge risk recognize consolidated statement tive use addition cost nonrefundable relate acquisition earning derivative designate cash flow hedge effective por licensing product receive regulatory approval bristolmyer squibb company annual reportmarkete alternative future use charge earning recently issue accounting standard incur december fasb issue revise sfas sfas sharebase paymentthis standard eliminate ability account share earning share base compensation transaction intrinsic valuebase method basic earning common share compute weightedaver apb opinion accounting stock issue employeesand age number share outstanding year dilute earning com require instead transaction account fairvalue mon share compute weightedaverage number share base method sfas effective financial statement issue outstanding year plus incremental share outstanding assume interim period begin june currently company exercise dilutive stock option restrict stock convertible instrument disclose pro forma net income relate pro forma income share information accordance sfas accounting stockbase foreign currency translation compensation sfas accounting stockbase compensation net asset company foreign subsidiary translate cost transition disclosurethe company evaluate impact dollar current exchange rate dollar effect arise statement material impact result operation translate net asset subsidiary change rate record december fasb issue fsp application sfas foreign currency translation adjustment account include accounting income taxesto tax deduction qualified comprehensive income production activity provide american job creation act effect adoption fsp material company consol stock compensation plan idate financial statement income taxis currently company apply accounting principle board apb opinion december fasb issue fas exchange nonmonetary accounting stockissue employee relate interpretation asset provision statement effective nonmonetary asset accounting stockbase compensation plan disclose pro forma exchange occur fiscal period begin june provi net income relate pro forma income share information accordance sion statement apply prospectively eliminate sfas accounting stockbase compensationand sfas exception fair value measurement nonmonetary exchange similar accounting stockbase compensation cost transition productive asset paragraph apb opinion accounting disclosure company recognize compensation expense stock nonmonetary transaction replace exception exchange option grant plan exercise price option date commercial substance adoption account pro grant equal fair market value date grant restrict nouncement expect material effect consolidated finan stock company recognize compensation expense straightline basis cial statement period restriction expire november fasb issue sfas inventory costsan follow table summarize company result pro forma basis amendment arb chapter standard require abnormal record compensation expense base fair value amount idle facility relate expense recognize current period grant date award plan consistent methodology pre charge require allocation fix production overhead scribe sfas cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin dollar million share datum ning june company evaluate impact state ment financial position result operation net earning june fasb issue fsp accounting disclosure report requirement relate medicare prescription drug improvement total stockbase employee compensation modernization act medicare act medicare act introduce expense include report net income prescription drug benefit medicare federal subsidy spon net relate tax effect sors retiree health care benefit plan provide benefit total stockbase employee compensation actuarially equivalent medicare fsp require expense determine fair value base effect new law account sfas employer method awards net relate accounting postretirement benefit pensionsthe company tax effect adopt fsp quarter retroactive january pro forma reduction net periodic benefit cost benefit basic earning share million base remeasurement accumulate postre report tirement benefit obligation january effect adoption pro forma fsp material company consolidate financial state dilute earning share ment note pension postretirement benefit plan report march emerge issue task force eitf reach consensus pro forma issue participate security twoclass method fas require use twoclass method compute earn option relate discontinued operation impact basic ing share enterprise participate security multiple diluted earning share note stockholder equity additional class common stock consensus effective fiscal period begin information ning march adoption eitf affect company consolidate financial statement bristolmyers squibb company annual reportin december fasb revise fin consolidation variable idate balance sheet million million december interest entity fin require variable interest entity consolidate respectively company company subject majority risk loss vari able interest entitys activity entitle receive majority entitys resid otsuka ual return fin require disclosure variable interest company worldwide commercialization agreement otsuka entity company require consolidate signif pharmaceutical ltd otsuka codevelop copromote abilify arip icant variable interest consolidation requirement fin revise iprazole treatment schizophrenia relate psychotic disorder apply immediately variable interest entity create january japan china taiwan north korea south korea philippine exist entity fiscal year interim period end march thailand indonesia pakistan egypt company begin copromote certain disclosure requirement apply financial state product otsuka puerto rico november june ments issue january regardless variable interest company receive marketing approval european entity establish accounting pronouncement material commission product currently copromote otsuka united effect consolidated financial statement kingdom germany copromote france spain company records alliance revenue contractual share net sale note alliance investment copromotion country exclude united kingdom record sanofiaventis expense relate product alliance revenue record company company agreement sanofiaventis sanofi codevel net sale base otsukas net sale copromotion coun opment cocommercialization avaproavalide angiotensin receptor try company recognize alliance revenue abilify ship antagonist indicate treatment hypertension plavix platelet risk reward ownership transfer otsukas customer inhibitor worldwide alliance operate framework geo company record net sale relate cost prod graphic territory america principally united states canada uct sell puerto rico latin american countries australia company exclusive right sell abilify number europe asia accordingly territory partnership form manage country europe america asia countries sale com central expense market research development royalty mence company record net sale relate cost prod supply finish product individual country general uct sell term agreement company purchase country level agreement copromote partnership product otsuka perform finish manufacturing sale form party sell brand comarket company customer agreement expire november party operate sell brand independently place puerto rico country european union agreement expire later respect plavix company exclusive right sell abilify agreement expire respect avaproavalide america australia tenth anniversary commercial sale country europe asia expiration patent exclusivity right company exclusive right sell abilify agreement expire applicable territory later tenth anniversary commercial sale country expi company act operating partner territory cover ration applicable patent country america australia own majority control interest company record revenue abilify million mil territory sanofis ownership interest territory lion million total milestone payment otsuka company consolidate country partnership result territory agreement december million record sanofis share result minority interest net taxis million expense acquire inprocess research development million million million remain million capitalize intangible asset company record sale territory comarkete country amortize cost product sell remain life agreement germany italy spain greece million million range year include million capi million talize payment million payment july attainment sanofi act operating partner territory cover europe marketing approval european union company amortize cost asia own majority financial control interest territory product sell million million million company ownership interest territory company unamortize capitalize payment balance million million account investment partnership entity territory december respectively equity method record share result equity net income affiliate consolidate statement earning company share net imclone income partnership entity tax million company commercialization agreement expire september million million imclone biopharmaceutical company focus develop tar company sanofi form alliance copromotion get cancer treatment codevelopment copromotion erbitux irbesartan company contribute irbesartan distribu united states february food drug administration tion rights united states sanofi pay company total fda approve biologics license application bla erbitux use million company account transaction sale combination irinotecan treatment patient epidermal growth interest license defer amortize million factor receptor egfrexpresse metastatic colorectal cancer income expect useful life license approximately refractory irinotecanbase chemotherapy use single agent year company recognize income million mil treatment patient egfrexpresse metastatic colorectal cancer lion million respectively unamortized intolerant irinotecanbase chemotherapy accordance portion defer income record liability section consol term agreement company pay imclone million bristolmyer squibb company annual report million pay march million pay march ment approximately sixteen year company recognize company pay million march milestone payment million payment income million milestone pay initial approval erbitux additional million payable fda ment defer record receivable december approval use treat additional tumor type agreement amortize income begin january remain imclone receive distribution fee base flat rate product rev useful life agreement addition company record mercks share enue north america addition company codevelopment codevelopment cost reduction research development expense copromotion right canada japan extent product commer mercks share copromotion cost reduction advertising prod cialize country uct promotion expense respect million milestone payment company pay imclone million expense quarter summary financial information acquire inprocess research development million follow summarize financial information company equity record additional equity investment eliminate income statement investment imclone joint venture sanofi europe asia effect portion milestone payment company economic claim ownership interest imclone company account million approval milestone pay march unaudite dollar million license acquisition amortize payment cost product sell expect useful life license approximately fourteen year revenue amortization expense million unamortized portion gross profit approval payment record intangible net mil net income lion december current asset company account investment imclone equity noncurrent asset method record share result equity net income affiliate current liability consolidated statement earning company record pre noncurrent liability tax charge million temporary decline market value imclone base decline value imclone share note restructure item company record investment imclone common stock activity december million million respectively company record pretax restructuring charge represent approximately imclone share outstanding million relate downsize streamline worldwide operation respectively share basis carry value imclone investment rationalization worldwide manufacturing operation charge closing market price imclone share december million relate primarily employee termination benefit approxi respectively compare respec mately employee include manufacture administrative sale tively december personnel europe north america asia latin america exit cost company determine equity share imclone net income loss million relate primarily lease termination cost item mil eliminate imclone result milestone revenue imclone recognize lion relate primarily relocation expense result consolidation preapproval milestone payment record company research facility charge partially offset adjustment additional equity investment share imclone result operation change estimate prior period reserve million principally company record net income million net loss mil reduce separation cost million gain sale lion million respectively company record research facility previously write restructure company expect net sale erbitux million complete restructuring activity follow table present detail provision restructuring merck item operating segment type company allocate restruc april company enter collaboration agreement ture charge business segment merck inc merck worldwide codevelopment copromotion muraglitazar company dual ppar peroxisome proliferator activate employee employee termination exit receptor agonist currently phase iii clinical development use treat dollar million termination benefit cost item total type diabetes december company submit new drug pharmaceutical application nda fda regulatory approval murgalitazar healthcare term agreement company receive million upfront payment entitle receive additional million milestone reduction reserve change estimate payment december subsequently receive january gain sale research property company entitle receive million additional payment provision restructure item achievement certain regulatory milestone company merck jointly develop clinical marketing strategy muraglitazar share addition company record million asset impairment equally future development commercialization cost copromote accelerate depreciation relate rationalization manufacturing product physician global basis merck receive payment base operation primarily cost product sell million research net sale level upfront payment million receive defer amortized income expect remain useful life agree bristolmyer squibb company annual reportemployee development relate upfront payment license agreement employee termination exit allocate business segment dollar million termination benefit cost item total pharmaceutical activity nutritional company record pretax restructuring charge healthcare million relate downsize streamline worldwide operation corporateother rationalization worldwide manufacturing operation charge subtotal reduction reserve change estimate million relate primarily termination benefit approximately employ provision restructure item ee include manufacture administrative sale personnel europe north america asia latin america items million relate prima addition million accelerate depreciation relate plan rily relocation expense result consolidation research facility shutdown research facility united states include charge partially offset adjustment change esti research development expense million inventory writeoff asso mate prior period reserve million principally higher ciate project include cost product sell anticipated proceed disposal asset reduce separation quarter company record pretax restructure charge cost company expect complete restructuring activity million severance exit cost associate consolidation follow table present detail provision restructure research development effort closure lease facility item operating segment type company allocate restruc result action impairment assessment perform long live ture charge business segment asset site accordance sfas company con clude million asset recoverable remain employee useful life asset mainly laboratory equipment leasehold improve employee termination exit dollar million termination benefit cost item total ment alternate use residual value accelerate year month reflect date abandonment facili pharmaceutical tie fourth quarter healthcare subtotal reduction reserve change estimate rollforward provision restructure item restructure charge spend liability associate prior current action follow addition company record million asset impairment employee termination exit cost accelerate depreciation relate rationalization manufacturing opera dollar million liability liability total tion cost product sell million research development relate upfront payment licensing agreement balance december allocate business segment charge spend activity change estimate company record pretax restructuring charge balance december million relate reduction elimination nonstrategic research charge effort consolidation research facility workforce reduction spending downsize streamline worldwide operation charge change estimate million relate employee termination benefit approximately employ balance december ee include research manufacturing sale administrative personnel charge million represent asset writedown include million impairment spending charge company investment deltagen million exit change estimate cost closure facility relate expense charge balance december offset adjustment prior period restructure reserve mil lion million lower expect separation cost liability include accrue expense consolidate bal million higher anticipate proceed disposal asset previ ance sheet ously write restructuring million project cancel addition million adjustment cost product sell note acquisition divestiture reflect reversal inventory reserve associate cancel february company complete divestiture adult project company complete restructuring activity nutritional business novartis novartis million include follow table present detail provision restructure million contingent achievement contractual requirement item operating segment type company allocate restruc satisfy million upfront payment supply agreement ture charge business segment company record pretax gain million million net tax include million contingent payment million reduction company goodwill associated mead johnson product line adult nutritional product record sale million bristolmyer squibb company annual reportin april company complete acquisition acordis specialty net earning discontinue operation include million fibre acordis headquartered united kingdom supply statement earning primarily relate reduction tax contin material convatec wound therapeutic line acquisition gency reserve relate spinoff zimmer holdings inc expect strengthen company leadership position wound therapy follow summary asset liability discontinue oper company purchase stock acordis million incur ation expect sell amount present derive million acquisition cost connection transaction additional historical financial information otn adjusted exclude cash million payment contingent achievement future sale volume intercompany receivables payable otn company purchase price acquisition allocate tangible identifi exclude divestiture addition goodwill relate otn able intangible asset acquire liability assume base esti december million exclude follow mate fair value acquisition date million million summary net asset dispose consider determine allocate inprocess research development represent esti gain sale date transaction consummate mate fair value acquire inprocess project consist primarily medicel wound therapeutic product reach technological feasi dollar million bility alternative future use expense esti mate fair value project determine employment asset discount cash flow model million assign identifiable intan receivables net gible asset predominantly patent excess purchase price current asset estimate fair value net asset acquire approximately million total current asset record goodwill acquisition account purchase property plant equipment method accordingly result operation include noncurrent asset accompany consolidated financial statement date acquisition total asset company complete sale brand product moisturel duricef result pretax gain million liability account payable note discontinue operation accrue expense december company commit plan sell otn total liability enter definitive sale agreement equity partner llc otn net asset sell lead specialty distributor pharmaceutical product officebase oncolo gists united states report distinct operating seg account payable balance primarily include payable mckesson ment transaction expect complete half corporation mckesson december usually pay sale price equal million plus sale price adjustment sale day month good ship precede month price adjustment base excess current asset current liability result timing account payable balance otn net liability work capital closing date sale price shall increase balance december decrease work capital exceed consolidated statement cash flow include otn business million closing date sale result pretax gain approximately period present company use centralized approach cash million subject sale price adjustment postclose management financing operation accordingly debt allo matter gain sale otn recognize closing date cat business cash inflow operate investing activity follow amount related otn business segregate discontinue operation million million year end continue operation report discontinue operation december respectively cash outflow reflect cost certain service provide otn company million year end december cost allocate company otn service include legal counsel insurance external audit fee payroll processing note earning share certain human resource service information technology system support numerator basic earning share net earning available com mon stockholder numerator diluted earning share net earning year end december available common stockholder interest expense add assume conversion convertible debt common share denomi dollar million nator basic earning share weight average number common net sale share outstanding period denominator diluted earning cost product sell share weight average share outstanding adjusted effect dilutive gross profit total operating expense earning income taxis provision income taxis net earning discontinue operation bristolmyer squibb company annual reportstock option computation basic earning common share note income taxis dilute earning common share follow component earning loss continue operation minority year end december interest income taxis year end december dollar million share dollar million earning continue operation discontinue operation net earning nonus net gain disposal net earning amount categorize base location tax basic authority average common share outstanding provisionbenefit income taxis attributable continue operation earning continue operation consist discontinued operation year end december net earning dollar million net gain disposal current net earning dilute nonus average common share outstanding conversion convertible debt bond defer incremental share outstanding assume exercise dilutive stock option nonus earning continue operation discontinue operation company provision income taxis dif net earning ferent compute apply statutory federal income net gain disposal tax rate earning continue operation minority interest income taxis result follow net earning earning minority interest income taxis weightedaverage share issuable exercise stock option dollar million include diluted earning share calculation earning continue operation dilutive million million million minority interest income tax statutory rate net earning include interest expense million million respectively add assume conversion convertible debt common effect operation share ireland puerto rico switzerland note expense net state local taxis component expense net net valuation year end december allowance change estimate dollar million contingent tax matter interest expense nondeductible reserve interest income anticipate dividend foreign exchange transaction loss net repatriation ajca net federal foreign expense net valuation allowance foreign interest expense reduce net interest swap gain million million million respectively interest income relate primarily cash cash equivalent investment marketable secu effective income tax rate earning continue operation ritie income include income thirdparty contract manufacturing minority interest income taxis compare royalty income gain loss disposal property plant equip high effective tax rate attributable pri ment marily million charge estimate defer taxis take fourth bristolmyer squibb company annual reportquarter anticipation repatriate approximately billion special repatriation revise result additional guidance clarify lan dividend companys nonus subsidiary pursuant ajca guage issue congress andor department treasury increase estimate contingent tax matter compare change companys factual assumption occur taxis charge related establishment valuation allowance certain provide balance undistribute earning approximately charitable contribution carryforward partially offset favorable resolution billion company invest expect invest undistrib certain tax refund claim increase foreign tax credit ute earning permanently offshore future earning repatri effect certain litigation reserve nondeductible increase ate united states company determine earning effective tax rate effective tax rate primarily decrease remit foreseeable future additional tax provision require effective tax rate benefit operation ireland puerto rico complexity tax law assumption switzerland treatment provision certain litigation reserve non practicable estimate amount income taxis deductible increase estimate contingent tax matter provide compare company settle federal income tax returns internal component current noncurrent defer income tax asset revenue service irs liability company establish liability possible assessment tax december authority result know tax exposure include limited transfer price certain tax credit state foreign tax matter dollar million amount represent reasonable provision taxis ultimately expect acquire inprocess research development pay need adjusted time information intercompany profit inventory item know december certain tax contingency foreign tax credit carryforward liability establish company reasonably defer income estimate possible contingency possible alternative minimum tax research contingency material effect change estimate related development credit carryforward contingent tax matter include rate reconciliation charitable contribution carryforward year end december company recognize income tax bene state tax net operating loss carryforward fit million settlement certain prior year tax matter foreign net operating loss credit determination company expect settlement tax litigation carryforward company reorganize structure ownership postretirement pension benefit nonus subsidiary principal purpose reorganization depreciation facilitate company ability efficiently deploy financial resource defer foreign currency gainloss united states company believe reorganization transac anticipate dividend repatriation ajca tion generally taxfree inside outside united states net possible tax authority particular jurisdiction assert tax liability arise reorganization transaction operation valuation allowance reorganize subsidiary reasonably possible predict defer tax asset net tax authority assert tax liability reasonably estimate possible loss range loss respect assert tax liability recognize company vigorously challenge assertion believe defer income taxis current prevail assurance result company defer income taxis noncurrent prevail final nonappealable determination possible foreign income taxis payable impact material liability noncurrent total note receivables major category receivables follow valuation allowance million december relate december million foreign state net defer tax asset million foreign dollar million state net operating loss tax credit carryforward million charitable contribution carryforward company currently believe trade receivable likely realize miscellaneous receivables income taxis pay year million million million respectively allowance current tax benefit realize exercise stock option charge receivables net capital excess par value stock amount million mil lion million respectively december company approximately billion undistributed earning foreign subsidiary company accrue provi sion million estimate deferred taxis fourth quarter anticipation repatriate approximately billion earning pursuant ajca company estimate tax cost relate bristolmyer squibb company annual reportnote inventory note goodwill major category inventory follow change carry goodwill year end december december follow dollar million pharmaceutical nutritional healthcare discontinue dollar million segment segment segment operation total finished good work process balance raw packaging material december inventory net purchase accounting adjustment note consignment reduction company experience substantial buildup sale adult saler inventory pharmaceutical business result sale incen nutritional tive offer company wholesaler october company business determine require restate sale earning correct error purchase price timing revenue recognition certain sale large allocation wholesaler pharmaceuticals business company determine adjustment sale account consignment model balance describe note accounting policiesrevenue recognition base december relationship nature incentive offer wholesaler inventory hold wholesaler note intangible asset consignment model transaction result defer revenue intangible asset major asset class follow million december defer revenue december december inventory account consignment model dollar million fully work company recognize approximately million patentstrademark million million defer revenue net sale license respectively net rebate return adjustment technology note property plant equipment accumulate amortization major category property plant equipment follow net carrying december dollar million amortization expense intangible asset majority land include cost product sell year end december building million million million respectively machinery equipment fixture expect amortization expense relate current net carrying construction progress intangible asset follow accumulate depreciation year end december dollar million property plant equipment net capitalize interest include category property plant equip ment show company capitalize interest million mil lion million year end december respectively later year bristolmyer squibb company annual reportnote shortterm borrowing company enter fixed float interest rate swap longterm debt billion longterm debt cash payment interest million include shortterm borrowing amount foreign bank million million respectively million million current installment longterm debt mil lion million december respectively short payment period term borrowing primarily consist commercial paper later million december average interest rate dollar million total year commercial paper outstanding december proceed longterm debt commercial paper issuance general corporate purpose average interest rate international shortterm borrowing obligation include shortterm borrowing company consolidate current installment longterm debt outstanding december balance sheet balance represent outstanding nominal longterm debt value respectively compare respec company convertible debenture include payment con tain feature describe tively december december company replace prior billion revolving credit facility new billion year revolve credit facility syndicate december company provide financial guarantee lender extendable anniversary date consent form standby letter credit performance bond majority lender facility contain financial covenant ratio consoli standby letter credit insurance company support date debt consolidate capital exceed company party liability program performance bond relate sale company compliance covenant inception new facility product foreign ministry health middle east borrowing outstanding revolve credit facility company believe significant majority guarantee expire december company unused shortterm line fund amount obligation present follow credit foreign bank million million december ing table respectively component longterm debt follow expiration period december dollar million total year year dollar million note standby letter credit note performance bond guarantee float rate convertible debenture note total commercial commitment note debenture debenture debenture yen note yen note euro interest yen principal term loan industrial revenue bond yen note yen note variable rate industrial revenue bond company outstanding billion convertible debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership company occur bond initial con version price conversion rate share adjustable depend average closing price applicable period maximum conver sion rate share bristolmyers squibb company annual reportnote stockholder equity accumulate balance relate component comprehen change common share treasury stock capital excess par value sive income loss follow stock restrict stock defer minimum accumulate loss pension available capital foreign currency effective liability sale comprehensive cost excess dollar million translation security adjustment security incomeloss dollar common treasury treasury par value restrict share million share issue share stock stock stock balance balance december december comprehensive issue pursuant stock income loss plan option balance amortization december restrict stock comprehensive lapse forfeiture income loss restrict stock balance purchase december balance december comprehensive income loss issue pursuant balance stock plan option december amortization restrict stock stock compensation plan lapse forfeiture companys stock incentive plan executive officer key restricted stock employee grant option purchase company common stock balance december market price date option grant option generally exercisable installment year issue pursuant stock fourth anniversary grant date maxi plan option mum term year additionally plan provide grant stock amortization appreciation right grantee surrender exercisable right restrict stock receive common stock andor cash measure excess market lapse forfeiture price common stock option exercise price restrict stock term stock incentive plan authorize share include balance outstanding share year number december share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise share available grant prior year share company prefer stock convertible share grant year share cancel forfeited expire common stock callable company option reduction available future grant number issue share prefer stock stock incentive plan provide grant common stock conversion share common stock key employee subject restriction continuous employment dividend declare common share restriction generally expire fiveyear period date grant compensation expense recognize restrict period december million million share restrict stock outstanding plan respectively million share restrict stock grant fair value bristolmyer squibb company annual reportthe stock incentive plan incorporate company longterm follow table summarize information concern company performance award award deliver form target stock compensation plan currently outstanding exercisable option number performance share threeyear cycle award base eps growth sale growth ulti number number security remain security issue weight average available future issuance mate payout modify company total stockholder return versus exercise exercise price equity compensation company proxy peer group threshold target meet outstanding option outstanding option plan exclude security performance period payment longterm perform right right reflect column plan category ance award plan maximum performance measure result share million share million maximum payout target december million million performance share outstanding equity compensation plan respectively million performance share grant plan approve fair value security holder teamshare stock option plan fulltime employee exclude key equity compensation executive grant option purchase company common stock plan approve market price date option grant company author security holder ize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share option outstanding option exercisable exercise plan december weight fair value option grant esti average weighted weighted range remain average average mate common share common share exercise number contractual exercise number exercise common share respectively date grant blackschole price outstanding life price exercisable price share million year share million optionprice model follow assumption dividend yield volatility riskfree interest rate expect life year stock option transaction december million share common stock reserve issuance pursuant stock plan option conversion prefer weight stock option relate discontinued operation include share common stock average available issue exercise price amount material share million option award plan share balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december authorize grant exercise lapse balance december bristolmyers squibb company annual reportnote financial instrument company use derivative instrument interest rate risk man company expose market risk change currency agement policy derivative instrument comprise principally fix exchange rate interest rate accordingly company utilize foreign float rate interest rate swap subject fairvalue hedge account exchange option forward contract offset effect exchange rate ing treatment company enter fix fluctuation anticipate foreign currency transaction primarily intercom float interest rate swap contract financial institution pany inventory purchase expect occur year notional amount swap billion billion company exposure net foreign currency denominate asset december respectively accordance sfas liability approximate million million accounting derivative instrument hedge activitiesthe company rec december respectively primarily europe japan ognize net reduction interest expense million million mexico canada million respectively reflect benefit low foreign exchange option contract forward contract hedge float rate obtain swap compare fix rate underlie anticipate transaction company primary foreign currency exposure debt swap contract underlie debt hedge relation dollar euro canadian dollar australian dollar record fair value result increase noncurrent asset japanese yen notional amount companys foreign exchange deriv million shortterm liabilitie million longterm debt million ative contract december million increase noncurrent asset longterm debt million million respectively derivative majority qualify december respectively swap contract generally hold hedge future anticipate cash flow effective portion change maturity company use derivative financial instrument fair value temporarily defer comprehensive income oci speculative purpose recognize earning hedge item affect earning company reclassify deferred loss sfas require company perform periodic assessment million million million respectively compre hedge effectiveness assessment determine derivative desig hensive income earning majority classify cost nate qualifying hedge continue highly effective offset change product sell cash flow hedge item ineffective portion fair value carry company financial instrument long defer oci include current period earning include cash cash equivalent marketable security account receivable year end december company recognize loss ineffec account payable approximate fair value december tive contract million fair value option forward contract longterm debt note difference liabilitie million million december fair value carry value material respectively record asset accrue liability december fair value foreign exchange contract note segment information base yearend currency rate blackschole model case company organize pharmaceutical company relate health option contract care business reportable segmentspharmaceutical addition foreign exchange hedge contract note nutritional healthcare pharmaceutical segment comprise company use foreign exchange forward contract hedge foreign cur global pharmaceutical international exclude japan consumer rency denominate monetary asset liability primary objective medicine business nutritional segment consist mead johnson pri foreign exchange forward contract protect dollar value marily infant formula business healthcare segment consist foreign currency denominate monetary asset liability effect convatec medical imaging consumer medicine united states volatility foreign exchange occur prior receipt settlement japan businesse dollar foreign currency denominate monetary asset company product sell principally wholesale retail liability primarily denominate japanese yen euro forward trade nationally internationally certain product sell contract designate hedge mark market drug manufacturer hospital clinic government agency medical incomeexpense notional fair value foreign profession wholesaler account approximately exchange forward contract december million respectively company total net sale sale million respectively wholesaler account respectively company total net sale wholesaler account approxi mately respectively company total net sale sale concentrate pharmaceutical segment bristolmyers squibb company annual reportbusiness segment earning minority interest net sale income taxis yearend asset dollar million pharmaceutical nutritional healthcare total segment corporateother total corporateother consist principally interest income interest expense certain administrative expense allocation business segment certain corporate program corporateother include gain sale businessesproduct line million million respectively accelerate depreciation million termination benefit exit cost million million million respectively asset writedown impairment charge million million respectively upfront milestone payment license agreement million million respectively litigation charge net million million million respectively acquire inprocess research development charge million include million asset impairment charge imclone pharmaceutical segment includes accelerate depreciation million certain manufacturing facility north america expect close relocation million retention million pharmaceutical include litigation settlement income million upfront pay ment licensing agreement million million accelerate depreciation asset manufacturing facility north america expect closed end million charge asset impairment million charge relocation expense million charge retention bonus benefit additionally pharmaceutical segment include charge acquire inprocess research development million corporateother asset include cash cash equivalent marketable security goodwill asset otn hold available sale certain asset capital expenditure depreciation dollar million pharmaceutical nutritional healthcare total segment corporateother total geographic area net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total bristolmyer squibb company annual reportnote lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal pen sion plan bristolmyers squibb retirement income plan fund policy contribute amount provide current service fund past service lia bility plan benefit base primarily year credit service participant compensation plan asset consist principally equity fixedincome security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country united states cost company defer benefit postretirement benefit plan include follow component pension benefit benefit dollar million service costbenefit earn year interest cost project benefit obligation expect return plan asset net amortization deferral net periodic benefit cost curtailment settlement total net periodic benefit cost company recognize impact medicare prescription drug improvement modernization act accordance fsp record million reduction net periodic benefit cost bristolmyers squibb company annual reportchange benefit obligation plan asset december plan underfunde accrue benefit obligation exceed company define benefit postretirement benefit accrue benefit liability december additional mini plan mum liability establish increase accrue benefit liability pension benefit benefit value underfunde accrue benefit obligation liability total dollar millions million million december respectively unfunded benefit equalization plan international plan benefit obligation additional minimum liability offset intangible asset million begin year million charge comprehensive income include stock service costbenefit holder equity million million december earn year respectively interest cost project accumulate benefit obligation define benefit pension plan benefit obligation million million december respectively plan participant contribution information pension plan accumulate benefit obligation excess curtailment settlement plan asset actuarial gainloss december plan amendment dollar million benefit pay exchange rate loss project benefit obligation benefit obligation accumulate benefit obligation end year fair value plan asset fair value plan asset attributable primarily unfunded benefit equalization plan begin year plan international market unfunde benefit equal actual return plan asset ization plan provide pension benefit employee compensation employer contribution irs limit fund taxadvantage manner plan participant contribution settlement transfer inout benefit pay exchange rate gain fair value plan asset end year fund status unamortized net obligation adoption unrecognize prior service cost unrecognized net actuarial loss net recognize amount recognize balance sheet consist prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive income net recognize bristolmyers squibb company annual reportadditional information pertaining company pension postretirement plan pension benefit benefit dollar million increase minimum liability include impact foreign currency fluctuation include comprehensive income weightedaverage assumption determine benefit obligation december pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december pension benefit benefit discount rate expect longterm return plan asset rate compensation increase december company expect longterm rate return assume health care cost trend rate effect amount pension plan asset target asset allocation public equity report health care plan onepercentagepoint change assume international private equity fix income health care cost trend rate follow effect approximate apply expect return public equity private equity fix income target allocation actual histor percentage percentage ical return relevant annualize return period end december dollar million point increase point decrease year year year pension plan asset represent approximately total company effect total service interest cost pension plan asset december disclose effect postretirement benefit obligation total company expect return asset pension plan impact international pension plan typically company asset allocation pension postretirement benefit employ aggressive asset allocation december expect return disclose benefit relevant asset invest manner pension plan asset pension benefit benefit international plan asset assume health care cost trend rate december public equity security debt security include cash private equity health care cost trend rate assume year total rate cost trend rate assume decline ultimate trend rate company investment strategy emphasize equity order achieve year rate reach high expect return long run low expense low require cash ultimate trend rate contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow cash contribution benefit payment rebalance target necessary investment diversi fie major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company annual reportbristolmyer squibb company common stock represent insurance outweighs benefits coverage protection loss plan asset december selfinsure product liability effective july company asset postretirement benefit commingle pension plan continue evaluate risk benefit determine insurance asset investment strategy identical describe need future pension plan plavix litigation contributions united states minimum contribution require company plan companys territory partnership alliance sanofi cash contribution pension plan plaintiff pende patent infringement lawsuit institute contribution pension plan company district court southern district new york entitle sanofisynthelabo taxdeductible contribution account retiree medical sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals benefit equal portion pension normal cost hold partnership apotex inc apotex corp sh contribution international pension plan expect sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi million range pharmaceutical hold partnership reddys laboratories ltd reddys laboratories inc shs sanofisynthelabo sanofi estimate future benefit payment synthelabo inc bristolmyers squibb sanofi pharmaceutical hold follow benefit payment reflect expect future service partnership teva pharmaceuticals usa inc teva pharmaceuticals appropriate expect pay industries ltd teva pharmaceuticals industries ltd benefit dismiss case proceeding involve plavix pension medicare institute outside united states significant proceeding dollar million benefit gross subsidy net pende canada describe suit file march september respectively base patent compo sition matter patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix suit base patent disclose year claim thing use clopidogrel prevent secondary ischemic event plaintiff later withdraw patent saving plan lawsuit plaintiff infringement position base defendant file principal define contribution plan bristolmyer squibb saving abbreviate new drug application anda fda seek approval investment program company contribution base employee sell generic clopidogrel bisulfate prior expiration composition contribution level company match company contribution matter patent defendant respond allege patent plan million million million invalid andor unenforceable apotex add antitrust counterclaim case consolidate discovery fact discovery close note legal proceeding october expert discovery complete november contingency trial occur early second quarter occur legal proceeding contingency later discovery commence action lawsuit claim proceeding investigation pende company territory partnership alliance sanofi company certain subsidiary accordance sfas plaintiff pende patent infringement lawsuit institute accounting contingency company record accrual district court district new jersey entitle sanofisynthelabo sanofi contingency probable liability incur synthelabo inc bristolmyers squibb sanofi pharmaceutical hold loss reasonably estimate matter involve antitrust security partnership watson pharmaceuticals inc watson laboratories inc patent infringement employee retirement income security act suit file october base patent amend erisa pricing sale marketing practice environmental disclose claim particular crystalline polymorph health safety matter product liability insurance coverage form hydrogen sulfate salt clopidogrel market plavix significant matter describe assurance case early stage discovery begin increase scope matter plavixis currently company large product rank net sale net future lawsuit claim proceeding investigation material sale plavix approximately billion billion year management continue believe previously disclose end december respectively year aggregate impact current reserve currently company expect plavix market exclusivity legal matter affect company reasonably likely material united states composition matter patent plavix find company result operation cash flow material infringe invalid andor unenforceable district court level fda financial condition liquidity approve defendant andas sell generic clopidogrel company decision obtain insurance coverage dependent generic competition plavix begin company exhausted market condition include cost availability exist time appeal generic competition likely result substantial decision result external factor availability insurance decrease sale plavix united states restrictive cost increase significantly plaintiff intend vigorously pursue enforcement company evaluate risk determine cost obtain patent right plavix possible time reasonably assess bristolmyer squibb company annual reportcome lawsuit company prevail lawsuit tevas generic product june court decision adverse time potential generic competition plavix generic com company kyorin date petition occur company believe unlikely erbitux october complaint file yeda research occur second half possible reasonably esti development company ltd yeda imclone aventis mate impact lawsuit company pharmaceuticals inc district court southern district new loss market exclusivity plavix subsequent develop york action allege seek individual associate yeda ment generic competition material company sale plavix name coinventor patent cov result operation cash flow material financial er therapeutic combination egfrspecific monoclonal antibody condition liquidity antineoplastic agent chemotherapeutic agent use treatment cancer yeda action successful yeda posi canada tion practice license practice invention result sanofisynthelabo sanofisynthelabo canada inc institute pro product competition erbitux occur hibition action federal court canada apotex inc apotex company party action unable predict outcome minister health response notice allegation apotex direct stage proceeding canadian patent cover clopidogrel bisulfate apotexs repligen corporation repligen massachusetts notice allegation noa indicate file abbreviate new drug institute technology mit file lawsuit united states district court submission ands clopidogrel bisulfate tablet seek approval district massachusetts imclone claim imclone manu notice compliance and expiration canadian patent facture sale erbitux infringe patent generally cover expire august apotexs noa allege process protein production mammalian cell repligen mit seek patent invalid infringe hear hold february damage base sale erbitux commence february february decision expect april patent expire repligen mit seek date statutory month stay impose approval apotexs extension patent company party action and expire unable predict outcome stage proceeding decision favorable apotex result generic product abilifyon august otsuka file united states patent market canada second quarter company believe trademark office uspto request reexamination composition outcome canada predictive outcome matter patent cover abilify antipsychotic agent treatment light different procedural substantive rule jurisdiction schizophrenia patent number patent sanofiaventis sanofisynthelabo canada inc institute expire extend pende supplemental prohibition action federal court canada novopharm limited protection extension grant otsuka determined original novopharm minister health response notice allegation patent application contain error description prior art refer novopharm direct canadian patent covering clopido ence identify wrong patent number addition otsuka take grel bisulfate novopharm noa indicate file ands clopidogrel opportunity bring citation attention uspto bisulfate tablet seek approval notice compliance uspto grant request reexaminationand reexamination and expiration canadian patent expire proceed ongoing reexamination proceeding allow uspto august novopharm noa allege patent consider patentability patent claim light correct patent invalid action early stage hear date set number newly cite document uspto expect final decision reexamination month united kingdom company otsuka believe invention claim december aircoat limit aircoat file nullity petition patent patentable prior art expect uspto reconfirm court session glasgow scotland nullity petition aircoat seek revo reexamination guarantee cation european patent register united come patentability patent reconfirm follow kingdom european patent cover inter alia clopidogrel bisulfate reexamination soon expect loss market exclusivity active ingredient plavix aircoat specifically allege claim abilify subsequent development generic competition european patent invalid revoke ground material company lack novelty andor lack inventive step avalideranbaxy laboratory limited ranbaxy serve notice file anda piv certification direct patent patent litigation formulation patent expire june ranbaxys piv notice tequinthe company kyorin pharmaceuticals ltd kyorin com assert propose generic formulation infringe patent mence patent infringement action march teva usa ranbaxys piv notice include challenge composi teva industries united states district court southern district tion matter patent currently expire september company new york relate antibiotic gatifloxacin kyorin hold partner sanofi currently evaluate ranbaxys piv notice composition matter patent company sell tequin teva avaproranbaxy serve notice file anda piv certifi industry dismiss case action relate tevas cation direct patent formulation patent file anda generic version gatifloxacin tablets certification expire june ranbaxys piv notice assert propose generic composition matter patent expire december formulation infringe patent ranbaxys piv notice invalid infringe filing suit place stay approval include challenge composition matter patent currently expire september company partner sanofi currently evaluate ranbaxys piv notice bristolmyer squibb company annual reporttequin injectable form apotex corp apotex sicor pharmaceutical possible time reasonably assess final outcome inc sicor american pharmaceutical partners inc app serve litigation reasonably estimate possible loss range loss notice file abbreviate nda piv certification direct respect litigation company prevail final nonappeal patent apotex sicor submit piv certification able determination litigation impact material patent patent composition matter patent expire december patent term extension security matter apply december patent cover spe period march company number cific form gatifloxacin tequin apotex sicor allege piv current officer name defendant number securi notice patent invalid apotex sicor app allege tie class action suit suit variously allege violation federal security propose generic formulation infringe patent law regulation connection different matter vanlev company currently evaluate piv notice discuss sale incentive wholesaler inventory level imclone imclone product erbitux discuss allega vanlev litigation tion concern vanlev transfer district court april june company chairman district new jersey consolidated action pende board chief executive officer charle heimbold remain action consolidate pende district chief scientific officer peter ringrose phd name defendant court southern district new york plaintiff file consolidated class number class action lawsuit allege violation federal security law action complaint april company certain current regulation action consolidate action officer allege class period october march district court district new jersey plaintiff claim consolidated class action complaint allege violation federal defendant disseminate materially false misleading statement andor security law connection thing company invest fail disclose material information concern safety efficacy com ment relationship imclone imclone product erbitux mercial viability product vanlev period november certain accounting issue include issue relate wholesaler inventory april sale incentives establishment reserve account certain asset plaintiff submit amend complaint add allega sale plaintiff seek compensatory damage cost tion company present chairman board chief executive expense march district court grant company officer peter dolan chairman board chief executive motion dismiss consolidated class action complaint dismiss officer charle heimbold chief scientific officer peter case prejudice plaintiff appeal dismissal second circuit ringrose phd disseminate materially false misleading statement court appeal court appeal appeal pende par andor fail disclose material information concern safety efficacy tie reach agreement principle settle action july commercial viability vanlev period april court appeal stay appeal remand action district march number relate class action make essentially court district court consider settlement july allegation file district court southern district court vacate clerk judgment order consider settle district new york action transfer district ment day district court enter order preliminarily approv court district new jersey ing settlement certify class settlement purpose pursuant company file motion partial judgment favor base term propose settlement claim action dis pleading plaintiff oppose motion seek amend miss litigation terminate defendant receive release complaint court grant deny company company pay million fund class member motion rule plaintiff amend complaint challenge certain november fairness hear district court approve set allege misstatement tlement judgment dismissing case prejudice settlement court certify separate class class relate period final company discuss recover insurance poli november april class relate period cie reflect financial statement portion million march march class certification propose class settlement approximately million share exclude set certification prejudice defendant right fully contest mer tlement pursuant request exclusion approximately million plaintiff claim plaintiff purport seek compensatory damage share hold plaintiff pende action discuss cost expense behalf shareholder respect class period company establish reserve liability possible time propose class period reasonably assess final outcome lawsuit accordance december company defendant gaap company determine amount represent mini motion summary judgment plaintiff claim final pretrial mum expect probable loss respect lawsuit eventual loss conference matter commence december sche relate lawsuit exceed reserve impact ule complete trial date set material company believe topend range january plaintiff move leave file amend complaint loss estimate seek combine class period expand class period addition action file early october new york state october march add allegation supreme court make similar factual allegation assert variety company peter dolan charles heimbold peter ringrose claim include common law fraud negligent misrepresen phd disseminate materially false misleading statement fail tation discovery take matter january disclose material information concern safety efficacy commercial company move dismiss complaint plaintiff file amend viability vanlev defendant oppose plaintiff motion complaint december make similar allegation add court schedule hear oral argument motion april allegations sec complaint issue august company file bristolmyers squibb company annual reporta motion dismiss amend complaint february plaintiffs consolidated amend complaint allege thing violation opposition motion dismiss march company federal security law breach fiduciary duty certain individual reply april relate action file september defendant connection company conduct concern november december make similar thing safety efficacy commercial viability vanlev discuss factual allegation assert claim similar amend company sale incentive certain wholesaler inventory complaint new york state supreme court action file october level wholesaler company investment relation company intend file motion dismiss relate action imclone imclone product erbitux allege anticompetitive behav briefing schedule identical action file october ior connection busparand taxol lawsuit allege malprac possible time reasonably assess final outcome litigation tice negligent misrepresentation negligence pwc plaintiff seek reasonably estimate possible loss range loss respect restitution rescission certain officer director compensation litigation company prevail final nonappealable determina allege improper insider trading proceed injunctive relief fee cost tion litigation impact material expense contribution certain officer allege liability consoli company number company current officer date security class action pende district court southern name defendant purport class action file october district new york discuss contribution indemnification state court cook county illinois complaint make factual allega pwc discovery take matter december tion similar settle federal class action southern company move dismiss consolidate amend complaint district new york assert common law fraud breach fiduciary motion dismiss administratively withdraw prejudice duty claim complaint purport assert claim behalf stock party right reinstate request similar action holder purchase company stock october pende new york state court plaintiff seek equitable relief damage hold stock march company remove cost attorney fee party currently engage discussion action northern district illinois february plaintiffs motion potential settlement action remand march company opposition april previously disclose august company enter plaintiff reply possible time rea final settlement sec concluding investigation concern certain sonably assess final outcome litigation reasonably estimate wholesaler inventory accounting matter settlement reach possible loss range loss respect litigation company consent copy attach exhibit prevail final nonappealable determination litigation company quarterly report form period end september impact material consent company agree admit deny november class action complaint file united states liability violate certain provision security law company district court eastern district missouri company agree establish million fund class shareholder healthcare resources inc current director distribute court supervision million fund officer behalf purchaser stock august include million civil penalty distribute certain company september class action complaint allege company shareholder plan distribution establish sec participate fraudulently inflate value stock allegedly engag settlement resolve ongoing investigation sec ing improper channelstuffe agreement company file activity certain current member company manage motion dismiss case january plaintiff opposition ment connection wholesaler inventory issue account motion dismiss march company reply matter investigation ongoing addition investigation april private security litigation reform act discovery attorney office district new jersey concern inventory automatically stay pende outcome motion dismiss plain accounting matter cover company settlement sec con tiff file motion partially lift automatic discovery stay february tinue company continue cooperate investigation company opposition motion march plaintiff reply march impact expect material erisa litigation begin october number company current december quarter company officer director name defendant shareholder deriva name defendant class action bring erisa tive suit pende district court southern district new york district court southern district new york district new number company current officer directors jersey action consolidated southern district new name defendant shareholder derivative suit file york caption bristolmyers squibb erisa litigation period march district court district lap amend consolidated complaint allege class period new jersey july district court district new jersey january march serve august order shareholder derivative lawsuit file court amend consolidated complaint bring behalf name plain transfer district court southern district new york tiff putative class consist participant bristolmyer subsequently district court southern district new york squibb company saving investment program saving plan order federal shareholder derivative suit consolidate plaintiff beneficiary benefit saving plan hold andor acquire company file consolidated amend verify shareholder complaint stock time class period exclude defendant heir certain member board director current officer predecessor successor assign name defendant pricewaterhousecooper pwc independent register public accounting company bristolmyer squibb company saving plan committee firm customary derivative suit company name committee thirteen individual presently serve committee defendant action nominal defendant company liable serve committee recent past charle heimbold peter damage suit specific relief seek company dolan past present chief executive officer respectively bristolmyer squibb company annual reportcompany amend consolidated complaint generally allege amend master complaint assert claim federal rico defendant breach fiduciary duty erisa class period antitrust statute state consumer protection fair trade statute thing continue offer company stock fund amend master complaint bring behalf main propose company stock investment alternative saving plan continue class definition subject amendment case invest company matching contribution company stock fund progress december propose class sum company stock fail disclose investment company stock marize person entity forward pay reimburse allegedly imprudent saving plan purchase company stock list drug medicare private contract january allege transaction prohibit expressly awp pricing standard person entity erisa finally defendant heimbold dolan allege breach forward pay reimburse portion purchase price fiduciary duty erisa fail monitor action drug cover card program base committee erisa claim predicate factual allegation awp class divide propose subclass similar raise security matter concern depend list drug question physicianadministere thing safety efficacy commercial viability vanlev company selfadministere sell pharmacy benefit manager specialty phar sale incentive certain wholesaler inventory level macy brandname generic drug september plaintiff saler company investment relation imclone imclone awp multidistrict litigation move certification propose plaintiff class product erbitux allege anticompetitive behavior connection party brief motion relate amend propose definition busparand taxol main class subclass discuss motion hear significant discovery date discovery currently court february stay october company defendant move company defendant move dismiss amend master dismiss amend consolidated complaint plaintiff oppose complaint ground fail state claim applicable statute motion dismiss defendant reply motion dismiss february court deny motion large administratively withdraw prejudice plaintiff court dismiss plaintiff claim failure plead cognizable rico request premotion conference intend ask court leave file enterprise accordingly court require company second amendment complaint second quarter company defendant answer amend master complaint court subsequently establish reserve liabilitie litigation million possi order defendant include company engage accelerate ble time reasonably assess final outcome litigation accor discovery respect remain allegation amend master dance gaap company determine reserve establish complaint allegation relate represent minimum expect probable loss respect litigation extend discovery schedule accelerate discovery close eventual loss relate litigation exceed reserve defendant january addition company defen impact material company believe topend dant obtain discovery name plaintiff nonpartie range loss estimate company prevail benefit consultant federal government health insurer final nonappealable determination matter impact material current schedule call expert report expert deposition summary judg result operation ment briefing liability issue half case commence nevada montana pennsylvania wisconsin pricing sale promotional practice litigation investigation illinois alabama kentucky attorney general attorney general company number pharmaceutical manufactur awp case case commence new york city new york ers defendant private class action action bring county new york city county awp case include fraud consumer nevada montana pennsylvania wisconsin kentucky illinois alabama protection claim similar amend master complaint certain attorney general city new york new york county state city county additional allegation defen pende federal state court relate price certain company dant include company violate state medicaid statute product federal case relate state court case thing fail provide state adequate rebate require remove federal court consolidate pretrial purpose federal law attorney general awp case montana action caption pharmaceutical industry average wholesale price litigation proceed respective state court mdl civ action cvpbs united states district series decision june september october affect court judge patti saris united states district court district montana attorney general case new york city county awp case massachusetts awp multidistrict litigation june private proceeding awp multidistrict litigation coordination plaintiff awp multidistrict litigation file amend master private class action court decline find medicaid rebate claims consolidated complaint amend master complaint amend master preempt federal law dismiss claim complaint contain set allegation company allege relate rebate payment drug manufacturer include company pharmaceutical manufacturer report claim relate company insufficiently plead court allow price certain drug product list drug company case proceed state law claim allege company misreporte effect falsely overstate average wholesale price awp publish awps company file answer claim remain industry compendia turn improperly inflate reimbursement pay montana attorney general complaint medical provider pharmacist prescribe administer company join defendant motion dismiss sell product consumer second allege company pennsylvania attorney general action decision file february certain defendant pharmaceutical manufacturer conspire pennsylvania commonwealth court grant motion dismiss program call card program fix awps ground plaintiff fail plead complaint requisite par certain drug available consumer program ticularity court give attorney general day replead july bristolmyers squibb company annual report nevada court deny company defendant motion previously disclose mid company initiate internal dismiss complaint state rico claim grant review certain sale marketing practice focus attorney general leave replead opinion base prior rul practice comply applicable antikickback law analyze ing awp multidistrict litigation court company defen practices respect compliance good price reporting rebate dant soon motion dismiss requirement medicaid program certain governmental attorney general awp case program reference medicaid rebate program applicable company number defendant private class action fda requirement company meet representative make awpbase claim remand awp multidistrict attorney office district massachusetts discuss review litigation arizona state court individual robert swanston assert receive related subpoena attorney office company claim arizona state law behalf allege class internal review expect continue resolution pende governmental son entity arizona pay prescription drug base awp investigation relate matter swanston action claim generally allege defendant drug manu company produce document actively cooperate inve facturer conspire inflate awps order date august tigation result assertion civil andor criminal claim arizona court deny defendant motion dismiss stay proceeding second quarter company increase reserve liability party currently brief plaintiff motion class certification relation pharmaceutical pricing sale marketing practice describe defendant paper february court swanston section million bring total reserve liabilitie action order discovery matter coordinated dis matter million possible time reasonably assess covery awp multidistrict litigation final outcome matter accordance gaap company october company add defendant determine represent minimum expect probable putative class action previously commence drug manufacturer loss respect matter loss include imposition federal court alabama case bring health care provider fine penalty administrative remedy andor liability additional rebate allegedly entitle federal statute section public amount eventual loss relate matter exceed reserve health service act discount price prescription drug dispense impact material company believe poor provider local area plaintiff health care provider contend topend range loss estimate company allege class provider authorize obtain discount prevail final nonappealable determination litigation price statute fact receive level discount investigation impact material entitle amend complaint company previously disclose company undertake analysis manufacturer assert claim directly federal statute method process calculate price report governmental state law unjust enrichment accounting company rebate pricing program relate pharmaceutical business join motion dismiss complaint file original manu analysis complete early base analysis company facturer defendant court approval applica identify need revision methodology process cal ble amend complaint culate report pricing relate rebate amount expect implement finally company defendant relate state court proceeding com revise methodology process begin report mence new york new jersey california tennessee proceed federal government agency primary responsibility rebate ing transfer awp multidistrict litigation pretrial purpose price reporting obligation center medicare medicaid services plaintiffs california new jersey action seek remand cms quarter addition revise methodology case state court california remand motion deny process company recalculate good price new jersey remand motion remain pende average manufacturer price require report company case preliminary stage company unable federal medicaid rebate agreement certain state agreement cor assess outcome possible effect business profitability respond revise rebate liability amount program reasonably estimate possible loss range loss respect case year period quarter base result company prevail final nonappealable determination company analysis time company record additional litigation investigation impact material liability equal estimate additional rebate liability result company number pharmaceutical manufactur propose revision material completion analysis er receive subpoenas document request early company finally determine estimate rebate liabil government agency seek record relate pricing sale market ity program threeyear period actually ing practice good price report drug cover medicare andor rebate pay company period medicaid request record come attorney office accordingly fourth quarter company reverse additional district massachusetts eastern district pennsylvania rebate liability record quarter record northern district texas civil division department justice additional reduction rebate liability estimate office inspector general department health human payment company propose revision update estimate service office personnel management conjunction submit review cms company anticipate submission civil division department justice state addition cms likely review department justice doj conjunc request information come house committee energy tion previously disclose subpoena receive company commerce senate finance committee connection investiga doj relate thing good price report drug cover tion committee currently conduct medicaid good medicaid discuss detail agency price issue position revision companys methodology calcula tion require completion governmental review company bristolmyers squibb company annual reportdetermine recalculation liability company ppain yale university publish result hemorrhagic identify program period similar pro stroke project conclude evidence suggestion gram necessary appropriate company believe base current ppa increase risk hemorrhagic stroke limited population information recalculation likely result material rebate november fda issue public health advisory request liability uncertainty surround recoverability manufacturer ppacontaine product voluntarily cease manufacturing company estimate overpayment arise review process describe marketing time ppacontaining product manufac company record reserve equal esti ture sell company comtrexliquigel formulation mate overpayment company remediate internal control naldeconon november company man process procedure company believe result propose ufacturer ppa contain product discontinue manufacture mar revision continue strengthen internal control keting ppacontaining product allow customer return unused company receive civil investigative demand attorney product possession general state missouri relate directtoconsumer advertising january company serve ppa lawsuit pravacholfor period company receive write confir company currently defendant approximately personal injury lawsuit mation attorney general july concluding investigation file behalf approximately plaintiff federal state court action take company company receive notice united states lawsuit involve multiple defendant putative class action lawsuit involve issue relate directto consumer claim plaintiff allege ppa cause hemorrhagic advertising file february circuit court jackson county ischemic stroke defendant aware risk fail warn con missouri kansas city caption richard summers bristolmyers squibb sumer fail remove ppa product plaintiff seek compen company company serve complaint march satory punitive damage federal case transfer removed action federal court action remand district court western district washington state court impact expect material phenylpropanolamine ppa product liability litigation mdl company number pharmaceutical manufactur district court deny motion class certification er name defendant action file california state class action lawsuit pende company litigation superior court oaklandjame clayworth bristolmyers squibb june district court issue rule effectively limit company allege defendant conspire fix price plaintiff claim hemorrhagic ischemic stroke ruling favorable pharmaceutical prevent importation foreign drug united defendant include inadmissibility expert testimony case allege state assert claim california cartwright act unfair compe injury occur day ingestion ppacontaining tition law plaintiff seek treble damage damage sus product case involve psychosis seizure cardiac injury taine restitution profit obtain defendant charge company expect dismiss additional case product artificially high price plaintiff injunction bar defendant plaintiff plaintiff allege injury occur charge plaintiff high price offer customer award rea day ingestion ppacontaining product sonable attorney fee cost relief court deem proper plaintiff suffer cardiac injury psychose plaintiff propounded interrogatory defendant serve serzone serzonenefazodone hydrochloride antidepressant objection response january party process launch company canada march meeting confer resolve dispute defendant response united states december company add black box warning objection plaintiff propound form interrogatory itsserzonelabel warn potential risk severe hepatic event include request admission request production document possible liver failure need transplantation risk death company prepare response objection discovery month black box warning add package insert request november company file demurrer action serzone number lawsuit include class action file plaintiff file opposition brief december company plaintiff allege company know company file reply brief january oral argument demur know hepatic risk pose byserzoneand fail adequately warn rer hold february order date february physicians user risk seek compensatory punitive dam court sustain demurrer court grant plaintiff leave file age medical monitoring refund cost purchasingserzone second amend complaint defendant company announce follow evaluation com response second amend complaint file march mercial potential product generic entry marketplace case preliminary stage company unable assess rapidly decline brand sale decide discontinue manufacture outcome possible effect business profitability reason sale product effective june ably estimate possible loss range loss respect case present company approximately lawsuit behalf company prevail final nonappealable determination liti approximately plaintiff pende federal state court gation impact material united states twentyseven case pende new york state court consolidated pretrial discovery addition product liability litigation approximately allege unfiled claim injury associate company party product liability lawsuit involve allegation withserzone august federal case transfer injury cause company pharmaceutical overthecounter medica district court southern district west virginia serzoneproducts tion majority lawsuit involve certain overthecounter medica liability litigation mdl discovery early stage tion contain phenylpropanolamine ppa companysserzoneand appear case involve liver failure june stadol prescription drug addition lawsuit company face district court dismiss class claim class action com unfiled claim involve product plaint purport class action file illinois num bristolmyers squibb company annual reportber class action complaint file company seek breast implant litigation company subsidiary certification personal injury class remain class action medical engineering corporation mec certain company remain complaint seek certification personal injury class addition defendant number claim lawsuit allege damage personal case file united states national class action file injury type result polyurethanecovered breast implant canada smoothwalle breast implant manufacture mec relate admit wrongdoe liability october company vast majority claim company direct lawsuit company enter settlement agreement respect resolve settlement trial claim united states territory regardingserzone settlement likewise claim potential claim company register agreement embody schedule payment dependent nationwide class action settlement approve federal district court class member develop qualify medical condition birmingham alabama revise settlement resolve demonstrate purchase tookserzone certain revise settlement company establish accrual criterion apply settlement subject final approval district court respect breast implant product liability litigation company believe appeal therefrom pursuant settlement agreement plaintiff class possible loss addition amount accrue material counsel file class action complaint see relief settlement class november district court conditionally certify temporary settle hormone replacement therapy hrt litigationin national ment class preliminarily approve settlement optout period end institute health begin clinical trial involve prempro estrogen april fairness hearing schedule june pursuant progestin premarin estrogen manufacture wyeth term propose settlement claim dismiss litigation july jama article report prempro subject terminate defendant receive release company com increase risk breast cancer heart attack blood clot stroke mit pay million fund class member class counsel prempro phase study stop july july right petition court award reasonable attorney fee company serve hrt lawsuit company product involve expense fee pay company reduce litigation estrace estrogenonly tablet estradiol generic estro money pay class member settlement company termi genonly tablet delestrogenan injectable estrogen ovcon oral con nate settlement base number claim submit number traceptive contain estrogen progestin product purport class member opt participate settlement sell company january august instead pursue individual claim company maintain estrace anda second quarter company establish reserve liabili company currently defendant approximately lawsuit involve tie lawsuit million possible time reasonably mention product file behalf approximately plaintiff assess final outcome lawsuit accordance gaap federal state court united states majority law company determine amount represent minimum suit involve multiple defendant company expect dismiss expect probable loss respect lawsuit eventual loss relate case product plaintiff allege lawsuit exceed reserve impact thing product cause breast cancer stroke blood clot car material company believe topend range diac injury woman defendant aware risk loss estimate fail warn consumer federal case transfer stadol stadol approve fda unschedule district court eastern district arkansas prempro wyeth opioid analgesic nasal spray february company ask fda product liability litigation mdl schedule stadol schedule low potential abuse drug post company vigorously defend product liability lawsuit marketing report suggestive inappropriate use product october believe majority case claim merit schedule drug company receive possible time reasonably assess final outcome number lawsuit involve stadol late number file suit company pende product liability lawsuit unfiled claim cer increase newly pass tort reform legislation effective tainty management opinion ultimate disposition january plaintiffs new suit previ matter material adverse effect company financial ously assert claim company allege injury position indicate company believe company announce follow evaluation commercial adequate selfinsurance reserve commercially available excess potential product generic entry marketplace rapidly insurance cover potential material loss relate product liability decline brand sale decide discontinue manufacture sale case claim product effective june company party approximately case pende behalf environmental proceeding total approximately plaintiff federal state court follow discussion describe environmental proceeding united states plaintiff claim company commit fraud fda governmental authority involve potential monetary sanction wrongfully promote stadol nonaddictive plaintiff allege threshold prescribe specific sec rule civil company fail adequately warn addiction dependency action environmental claim result significant liability risk associate use stadol company reach agree update ongoing matter resolution matter disclose ment principle settle lawsuit involve approximately plain recent public filing summary environmental remediation cost tiff addition lawsuit approximately active allege result internal audit perform company facility unfiled claim majority case claim pende mississippi hopewell indicate operation site wastewater treatment plant second quarter company recover insurance proceed relate discharge compliance new jersey million respect stadol case water pollution control act implement regulation term bristolmyer squibb company annual reportcompany discharge permit company report finding new finance portion study epa estimate study cost mil jersey department environmental protection njdep february lion roughly half finance private party group study enter settlement agreement njdep november pay lead cleanup action direct epa army corp penalty result audit suggest engineer company work cooperatively group party adverse impact public health company take receive njdep directive andor epa notice explore potential continue corrective action address identify deficiency resolution directive address risk collateral claim prevent future occurrence company believe caused contribute contamina environmental protection agency epa investigate industrial tion low passaic river watershe company inform commercial facility use refrigeration equipment njdep willing discuss allegation company contain ozonedeplete substance od enforce compliance directive recent communication cooperate group njdep regulation govern prevention service repair leak ods require state responsible party cooperate njdep ment recently company perform voluntary corporatewide audit form damage assessment restoration civil action recover facility puerto rico use odscontaine refrigeration remedial cost treble damage administrative cost penalty equipment company submit audit report epa november late group federal agency designate trustee natural identify potential violation od requirement resource affect contamination passaic river watershe facility currently discussion epa resolve matter approach cooperate group solicit interest funding cooperative addition matter cover company audit report letter epa study possible natural resource damage nrd area study pre epa previously send company wholly own subsidiary mead sumably dovetail ongoing epa study ideally johnson request information compliance od require joined njdep coordinate action njdep seek ment facility evansville indiana company respond directive discussion federal trustee ongoing extent request june epa currently process review liability company face directive epa notice let information company provide epa determine ter respect future nrd action claim federal trustee evansville facility facility violation applicable od contribution responsible party determined requirement company subject penalty andor require october michigan department environmental quality convert replace refrigeration equipment use nonod approve substitute mdeq send company letter violation lov allege january njdep send company approximately unspecified period time emission certain digestion tank mead company information request letter relate site north brunswick johnson zeeland michigan facility exceed applicable limit facil township waste material squibb son squibb ity renewable operating air permit lov require company cor wholly own subsidiary company disposed rective action submit compliance program report mdeq fill material contain industrial waste heavy demand fine penalty enforcement action result metal excess residential standard discover fall penalty injunctive relief company contest allegation expansion project north brunswick township high school lov company mdeq work revision number neighbor residential property adjacent public park area company air use permit predict ultimate outcome school board township current owner site certainty permit revision resolve matter additional conducting jointly finance soil remediation work work plan enforcement action need continue contest lov approve njdep ask company contribute cost december company njdep enter remediation company discussion njdep site owner administrative consent order aco concern allege violation potentially responsible party scope cost work new jersey air pollution control act implement regulation require address know condition concern recently offer company new brunswick facility pursuant aco company agree negotiate school board township term cooperative submit permit application create facilitywide emission cap pay funding agreement allocation process company actively inve administrative fine approximately obligation tigate historic use site include company possible connec satisfied early subsequently february aco tion date claim assert company amend provide company install new cogeneration turbine september njdep issue administrative enforcement new brunswick facility december obtain air directive notice new jersey spill compensation control act mit include require cogeneration turbine december require company approximately company perform estimate cost new cogeneration turbine approximately assessment natural resource damage implement unspecified interim million remedial measure restore condition low passaic river company defendant class action suit file supe directive allege company liable historically send bulk rior court puerto rico february resident ward waste inland chemical company facility newark repro municipality barceloneta allege air emission government cesse release hazardous substance facility own operate wastewater treatment facility say municipality migrate newark bay continue adverse impact cause respiratory ailment violate local air rule low passaic river watershe subsequently epa issue notice company believe wastewater discharge treatment facility letter comprehensive environmental response compensation material compliance term company permit company liability act cercla numerous party include company believe litigation resolve immaterial seek cooperation study condition substantially suit year old initial stage stretch passaic river subject njdep directive group issue class certification pende event adverse judgment party enter consent agreement epa company ultimate financial liability great anticipate bristolmyer squibb company annual reportthe company responsible state federal foreign aforementioned indemnity applicable certain prior period insur law include cercla certain cost investigate remediate con ance policy certain indemnification payment covered tamination result past industrial activity company current company director officer insurance coverage company mer site waste disposal reprocess facility operate predict certainty extent company recover party company typically estimate cost base information insurer indemnification payment connection litigation obtain epa counterpart state agency andor study prepare matter regulatory action describe independent consultant include total estimate cost site july company insurer federal insurance expect costshare potentially responsible party company federal file lawsuit new york supreme court prp company accrue liability probable reasonably company current officer member board estimable december company estimate director seek rescission alternative declaration allow federal share total future cost site approximately million avoid payment certain director officer insurance policy million respectively record liability represent sum certain fiduciary liability insurance policy respect potential liability good estimate simple estimate reasonably estimate arise connection matter describe vanlev litigation minimal probable range cost take security matter erisa litigation section discovery account potential recovery party currently take matter party currently engage discussion expect company pay million exclude legal fee potential settlement action year investigation remediation matter october companys insurer international include liability cercla onsite remedial obligation business insurance ltd sri inform company intend try possible predict certainty outcome envi avoid certain insurance policy issue company ground ronmental proceeding ultimate cost remediation company allege material misrepresentation nondisclosure initiate believe reasonably possible expenditure company arbitration proceeding london england sri indicate intend incur excess exist reserve material adverse effect rely allegation similar describe security matter business financial position result operation section support avoidance action matter october sec notify company conduct note subsequent event informal inquiry activity certain company german pharma january company announce plan divest ceutical subsidiary employee andor agent company believe canadian consumer medicine business year end december secs informal inquiry encompass matter currently investiga sale consumer medicine brand canada total tion staatsanwaltin prosecutor munich germany uncertain approximately million company consumer medicine business time company believe inquiry investigation concern japan asia pacific latin america europe middle east africa potential violation foreign corrupt practice act andor german law include plan divestiture company cooperate sec german authority november company medarex inc medarex enter possible time reasonably assess final outcome mat worldwide collaboration develop commercialize mdx fully human ter reasonably estimate possible loss range loss antibody investigational product target ctla receptor mdx company conduct internal review pharmaceutical opera develop medarex currently phase iii clinical development tion mexico total sale million month treatment metastatic melanoma collaboration agreement effec end december broad review include area compliance tive january time company cash payment legal financial regulatory requirement company standard million medarex expense research development business conduct ethic review ongoing time additional million equity investment medarex company unable assess impact result investiga tion company indemnification officer director companys corporate bylaw require extent permit law company shall indemnify officer director judgment fine penalty amount pay settlement include legal fee appeal incur connection civil criminal action proceeding relate service company subsidiary bylaw provide limit indemnification indemnification permit case willful misconduct know violation criminal law improper sonal benefit permit law state delaware company year purchase director officer insurance cover age cover claim director officer amount type coverage varied period period dictate market con dition excess policy provide additional coverage litigation matter regulatory action describe involve certain company current director officer cover bristolmyer squibb company annual reportnote select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security dollar million share datum net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security note earning share quarter add amount year period compute discrete basis include litigation charge million million million second fourth quarter respectively second quarter include litigation settlement income million second fourth quarter include gain sale mead johnson adult nutritional business million million million million respectively second fourth quarter include provision restructure item million million million million respectively sec ond fourth quarter include upfront payment license agreement million million million million respectively second quarter include writeoff acquire inprocess research development million million respectively include litigation settlement charge million million second fourth quarter respectively second quarter include litigation settlement income million million million respectively second fourth quarter include provision restructure item million million million million respectively second fourth quarter include reversal prior period restructure item million million million respectively fourth quarter include upfront payment license agreement million million respectively common equivalent share exclude computation dilute earning share effect antidilutive follow million second fourth quarter quarter quarter quarter year bristolmyers squibb company annual reportreport management management responsibility financial statement management responsible preparation presentation integrity financial information present annual report accompany consolidated financial statement prepare conformity accounting principle generally accept united states america gaap apply certain estimate judgment require management opinion consolidated financial state ment present fairly company financial position result operation cash flow audit committee board director meet regularly internal auditor pricewaterhousecooper llp pwc company independent register public accounting firm management review account internal control structure financial reporting mat ter internal auditor pwc free access audit committee set forth company standard business conduct ethic company firmly commit adhere high standard moral ethical behavior business activity management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate frameworkissue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliabili financial reporting preparation financial statement external purpose accordance gaap inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree com pliance policy procedure deteriorate pricewaterhousecooper llp pwc independent register public accounting firm audit company consolidated financial statement include annual report issue report management assessment effectiveness company internal control financial reporting appear annual report peter dolan chairman board chief executive officer andrew bonfield senior vice president chief financial officer march bristolmyers squibb company annual reportreport independent register public accounting firm board director stockholder bristolmyers squibb company complete integrate audit bristolmyer squibb company company consolidated financial statement internal control financial reporting december audits consolidated financial statement accordance standard public company accounting oversight board united states opinion base audit present consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company subsidiary december result operation cash flow year period end december con formity accounting principle generally accept united states america financial statement responsibility company manage ment responsibility express opinion financial statement base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain rea sonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate manage ment evaluate overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting opinion management assessment include management report internal control financial reporting appear annual report company maintain effective internal control financial reporting december base criterion establish internal controlintegrate frameworkissued committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate frameworkissue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform pro cedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control finan cial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transac tion disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effec tiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp philadelphia march bristolmyers squibb company annual reportcontrol procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief finan cial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective provide reason able assurance company record process summarize report information company disclose report company file submit securities exchange act amend time period specify sec rule form management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate frameworkissue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inade quate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pwc independent register public accounting firm audit company financial statement include annual report issue report management assessment effectiveness company internal control financial reporting december appear annual report status previously disclose internal control item make evaluation effectiveness design operation disclosure control procedure management consider signifi resource devoted substantial action take company past year remediate reportable condition define standard establish american institute certify public accountant relate internal control financial reporting income taxis initially identify communicate company audit committee pwc connection audit company consolidated financial statement year end december repeat year end december reportable condition identify pwc need enhance income tax accounting function provide timely analysis reconciliation income tax provision relate income tax asset liability action take company include engage outside consultant assist company personnel conduct comprehensive detailed review certain company income tax reporting account company continue strengthen internal control financial reporting income taxis effort include continue work outside consultant make significant personnel change include hire new vice president tax increase number tax department key personnel implement policy procedure enhance communication business unit tax department financial reporting personnel ensure comprehensive appropriate timely review matter implement new update exist tax accounting policy provide training policy base evaluation chief executive officer chief financial officer conclude december internal control financial reporting income taxis issue sufficiently remediate discuss note legal proceeding contingency management identify need remediate deficiency internal con trol methodology process calculate price report governmental rebate pricing program relate pharmaceutical busi ness conduct evaluation chief executive officer chief financial officer consider substantial effort undertake company remediate internal control deficiency include retain outside consultant subject matter expertise conduct exhaustive review exist methodology process train employee implementation revise methodology process base review chief executive officer chief financial officer conclude company internal control methodology process calculate price describe sufficiently remediate change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting bristolmyer squibb company annual reportfiveyear financial summary dollar million share datum income statement datum net sale earning continue operation minority interest income taxis earning continue operation earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result set forth table management discussion analysis financial condition result operation expense year discussion item management discussion analysis financial condition result operationsexpense note alliance investment note restructure item note acquisition divestiture note discontinued operation exclude discontinue operation otn year clairol zimmer include discontinue operation year bristolmyer squibb company annual reportboard director management executive committee board director management executive committee robert allen peter dolan retire chairman chairman chief executive officer chief executive officer att corporation abd lamberto andreotti lewis campbell senior vice president president international chairman president chief executive officer stephen bear textron inc abc senior vice president human resource vance coffman andrew bodnar chairman retire chief executive officer senior vice president strategy lockheed martin corporation medical external affairs james cornelius andrew bonfield nonexecutive chairman senior vice president chief financial officer guidant corporation cirm carlo notaristefani peter dolan president technical operation chairman chief executive officer bristolmyers squibb company wendy dixon phd president global marketing ellen futter chief marketing officer president american museum natural history donald hayden executive vice president president americas louis gerstner retire chairman chief executive officer anthony hooper ibm corporation president pharmaceuticals laurie glimcher tamar howson irene heinz give professor immunology senior vice president corporate harvard school public health business development professor medicine harvard medical school john mcgoldrick leif johansson executive vice president general counsel president volvo chief executive officer volvo group elliott sigal phd chief scientific officer president james robinson iii pharmaceutical research institute cofounder general partner robert zito rre ventures bcd senior vice president corporate affairs louis sullivan president emeritus morehouse school medicine audit committee committee director corporate governance compensation management development committee executive committee bristolmyers squibb company annual reportstockholder information product namesand company common stock program appear ticker symbol bmy free copy company annual italic trademark bristolmyers new york stock exchange report fiscal year squibb company sub pacific stock exchange end december contact sidiary company global product secretary refer register annual meeting bristolmyer squibb company approve trademark stockholder park avenue specifically note tuesday new york hotel dupont abilifyis trademark otsuka market street available pharmaceutical company ltd wilmington wwwbmscominvestors avapro avalide plavixand iscover trademark sanofiaventis stockholder service recent certification delestrogeni trademark program companys chief executive officer king pharmaceuticals inc inquiry concern stockholder chief financial officer pursuant section account stock transfer matter sarbanesoxley act estraceis trademark galen include address change elimination file exhibit company chemical ltd duplicate mailing dividend reinvest company file emsamis trademark somerset ment direct deposit new york stock exchange pharmaceuticals inc dividend direct recent annual ceocertification company transfer agent registrar require section erbituxis trademark imclone new york stock exchange list system incorporate mellon investor service company manual gleevec trademark novartis challenger road glucophage glucophage xrand ridgefield park follow report glucovanceare trademark merck wwwmelloninvestorcom available write sant sas associate merck corporate affair kgaa darmstadt germany outside bristolmyers squibb company tdd telephone service park avenue javloris trademark pierre fabre hear impair new york mdicament kaletrais trademark outside bristolmyers squibb foundation abbott laboratories inc sustainabilityenvironmental programs dividend reinvestment plan political contribution ovconis trademark registered stockholder stock eeo report warner chilcott inc hold hold premarinand premproare trademark share company stock partic wyeth ipate stockholderpaid dividend shapedowndevelope reinvestment plan drip cover university california include safekeepe saleofstock feature hold few share truvadais trademark gilead eligible participate october team sciences inc safekeepe saleofstock feature cyclist compose cancer direct registration option survivor physician nurse care giver researcher begin eightday transcontinental odyssey los angeles washington join point copyright way cancer survivor sixtime bristolmyers squibb company tour france champion lance right reserve armstrong bristolmyers squibb tour hopeteam help educate design photograph write americans nationwide bristolmyer squibb promise cancer clinical trial corporate affair department importance cancer research print recycle paper help speed search curelopqr hopetriumph miracle medicine park avenue new york telephone wwwbmscom